FINALMENTE.....la
FDA
conferma che i Vaccini possono produrre l'
Autismo
http://www.getcancercure.com/fda-announce-that-dtap-vaccine-causes-autism/
STUDI, RICERCHE su
VACCINI ed Autismo (English)
Conjugate vaccines may predispose children to autism
spectrum disorders.
the potential effects of conjugate vaccines on neural
development merit close examination. Conjugate vaccines
fundamentally change the manner in which the immune
systems of infants and young children function by
deviating their immune responses to the targeted
carbohydrate antigens from a state of
hypo-responsiveness to a robust B2 B cell mediated
response. This period of hypo-responsiveness to
carbohydrate antigens coincides with the intense
myelination process in infants and young children, and
conjugate vaccines may have disrupted evolutionary
forces that favored early brain development over the
need to protect infants and young children from capsular
bacteria.
http://www.ncbi.nlm.nih.gov/pubmed/21993250
Serological association of
measles virus and human herpesvirus-6 with brain
autoantibodies in autism.
Considering an autoimmunity and autism connection, brain
autoantibodies to myelin basic protein (anti-MBP) and
neuron-axon filament protein (anti-NAFP) have been found
in autistic children. In this current study, we examined
associations between virus serology and autoantibody by
simultaneous analysis of measles virus antibody (measles-IgG),
human herpesvirus-6 antibody (HHV-6-IgG), anti-MBP, and
anti-NAFP. We found that measles-IgG and HHV-6-IgG
titers were moderately higher in autistic children but
they did not significantly differ from normal controls.
Moreover, we found that a vast majority of virus
serology-positive autistic sera was also positive for
brain autoantibody: (i) 90% of measles-IgG-positive
autistic sera was also positive for anti-MBP; (ii) 73%
of measles-IgG-positive autistic sera was also positive
for anti-NAFP; (iii) 84% of HHV-6-IgG-positive autistic
sera was also positive for anti-MBP; and (iv) 72% of
HHV-6-IgG-positive autistic sera was also positive for
anti-NAFP. This study is the first to report an
association between virus serology and brain
autoantibody in autism; it supports the hypothesis that
a virus-induced autoimmune response may play a causal
role in autism.
http://www.ncbi.nlm.nih.gov/pubmed/9756729
Effectiveness of pertussis
vaccines for adolescents and adults: case-control study
The adjusted estimate of effectiveness of Tdap
vaccination against pertussis was 53.0.
http://www.bmj.com/content/347/bmj.f4249
Neurologic Adverse Events
Following Vaccination (Progress in Health Sciences Vol.
2(1) 2012•pp 129-141.)
“Conclusions: Despite the assurances of the necessity
and safety of vaccinations, there are more and more
questions and doubts, which both physicians and parents
are waiting to be clarified… It seems that it would be
worthwhile to apply the precautionary principle – the
ethical principle (from 1988) according to which if
there is a probable, although poorly known, risk of
adverse effects of new technology, it is better not to
implement it rather than risk uncertain but potentially
very harmful consequences.”
http://progress.umb.edu.pl/sites/progress.umb.edu.pl/files/129-141.pdf
Abnormal
measles-mumps-rubella antibodies and CNS autoimmunity in
children with autism.
“Thus the MMR antibody in autistic sera detected measles
HA protein, which is unique to the measles subunit of
the vaccine. Furthermore, over 90% of MMR
antibody-positive autistic sera were also positive for
MBP autoantibodies, suggesting a strong association
between MMR and CNS autoimmunity in autism. Stemming
from this evidence, we suggest that an inappropriate
antibody response to MMR, specifically the measles
component thereof, might be related to pathogenesis of
autism.”
http://www.ncbi.nlm.nih.gov/pubmed/12145534
Influenza: marketing vaccine by marketing disease
Closer examination of influenza vaccine policies shows
that although proponents employ the rhetoric of science,
the studies underlying the policy are often of low
quality, and do not substantiate officials’ claims. The
vaccine might be less beneficial and less safe than has
been claimed, and the threat of influenza appears
overstated.
http://www.bmj.com/content/346/bmj.f3037
An unmasking phenomenon in
an observational post-licensure safety study of
adolescent girls and young women.
Our recent experience in a post-licensure safety study
of autoimmune conditions following the quadrivalent
human papillomavirus vaccine in 189,629 girls and young
women ages 9-26 years led us to question the adequacy of
the exclusion of Day 0 events to prevent the erroneous
association of prevalent conditions with vaccination. Of
the 18 confirmed cases of Graves’ disease diagnosed in
days 1-60 following vaccination, only 6 cases appeared
to be truly new onset. Among the remaining 12 cases, 2
cases had abnormal thyroid stimulating hormone or
thyroxine labs drawn prior to or on Day 0 but had no
documented pre-existing symptoms. The other 10 cases had
mention of symptoms of hyperthyroidism referencing a
period prior to first HPV-4 dose. This ‘unmasking’
phenomenon, due to health care visits that include
vaccination and new workups of preexisting symptoms, may
not be adequately controlled through the exclusion of
Day 0 events.
http://www.ncbi.nlm.nih.gov/m/pubmed/22580356/
How aluminum, an
intracellular ROS generator promotes hepatic and
neurological diseases: the metabolic tale
Metal pollutants are a global health risk due to their
ability to contribute to a variety of diseases. Aluminum
(Al), a ubiquitous environmental contaminant is
implicated in anemia, osteomalacia, hepatic disorder,
and neurological disorder. In this review, we outline
how this intracellular generator of reactive oxygen
species (ROS) triggers a metabolic shift towards
lipogenesis in astrocytes and hepatocytes. This
Al-evoked phenomenon is coupled to diminished
mitochondrial activity, anerobiosis, and the channeling
of α-ketoacids towards anti-oxidant defense. The
resulting metabolic reconfiguration leads to fat
accumulation and a reduction in ATP synthesis,
characteristics that are common to numerous medical
disorders. Hence, the ability of Al toxicity to create
an oxidative environment promotes dysfunctional
metabolic processes in astrocytes and hepatocytes. These
molecular events triggered by Al-induced ROS production
are the potential mediators of brain and liver
disorders.”
http://link.springer.com/article/10.1007%2Fs10565-013-9239-0
Waning of Maternal
Antibodies Against Measles, Mumps, Rubella, and
Varicella in Communities With Contrasting Vaccination
Coverage
Conclusions: Children of mothers vaccinated against
measles and, possibly, rubella have lower concentrations
of maternal antibodies and lose protection by maternal
antibodies at an earlier age than children of mothers in
communities that oppose vaccination. This increases the
risk of disease transmission in highly vaccinated
populations.
http://jid.oxfordjournals.org/content/early/2013/04/29/infdis.jit143.full
“vaccine injury is so
rare..don’t worry about it!” who has heard this?
“The Health Resources and Services Administration (HRSA)
is publishing this notice of petitions received under
the National Vaccine Injury Compensation Program.. A
petition may be filed with respect to injuries,
disabilities, illnesses, conditions, and deaths
resulting from vaccines described in the Vaccine Injury
Table… Set forth below is a list of petitions received
by HRSA on * March 13, 2013, through April 30, 2013.*”
[take note of #7 and #17..]
1. Tory J. and Sarah E.
Moody on behalf of Victorya E. Moody, Bedford, Indiana,
Court of Federal Claims No: 13-0190V.
2. Pamela Jean Peguess, Memphis, Tennessee, Court of
Federal Claims No: 13-0191V.
3. Eileen Goeschel, Sarasota, Florida, Court of Federal
Claims No: 13-0199V.
4. Kearsten Demczuk, Park Ridge, Illinois, Court of
Federal Claims No: 13-0205V.
5. Howard Reddy and Hanan Tarabay on behalf of Andrew
Howard Reddy, Pensacola, Florida, Court of Federal
Claims No: 13-0208V.
6. Mona Marie Troup, Everett, Washington, Court of
Federal Claims No: 13-0209V.
7. Angel Blackstone on behalf of S.B., Deceased, Trenton,
New Jersey, Court of Federal Claims No: 13-0213V.
8. Isidra Durwin, Sarasota, Florida, Court of Federal
Claims No: 13-0214V.
9. Nancy and Sandro Giannetta on behalf of A.M.G.,
Sarasota, Florida, Court of Federal Claims No: 13-0215V.
10. Kimberly Pedersen, West Allis, Wisconsin, Court of
Federal Claims No: 13-0216V.
11. Charles and Jeannie Maikish on behalf of S.M., Nyack,
New York,Court of Federal Claims No: 13-0217V.
12. Ina Scanlon, Muncie, Indiana, Court of Federal
Claims No: 13-0219V.
13. David Stachlewitz on behalf of H.G.S., Glendale,
Arizona, Court of Federal Claims No: 13-0220V.
14. Mary E. Thompson, Brookport, Illinois, Court of
Federal Claims No: 13-0222V.
15. Matthew Gorski, Wynnewood, Pennsylvania, Court of
Federal Claims No: 13-0224V.
16. Woodrow Coffey, Jr., Irvine, California, Court of
Federal Claims No: 13-0225V.
17. Stephen Warren on behalf of Taylor Warren, Deceased,
New York, New York, Court of Federal Claims No:
13-0226V.
18. Robert Wiggins, Nashville, North Carolina, Court of
Federal Claims No: 13-0228V.
19. Peggy Kalmeyer, Depew, New York, Court of Federal
Claims No: 13-0230V.
20. Rosemary and Wayne Trezza on behalf of P.T., West
Orange, New Jersey, Court of Federal Claims No:
13-0231V.
21. Jane Tomassetti, Woodbury, Minnesota, Court of
Federal Claims No: 13-0234V.
22. Everett Johnson, Sr., Ashland, Kentucky, Court of
Federal Claims No: 13-0235V.
23. Edwin W. Fockler, Sarasota, Florida, Court of
Federal Claims No: 13-0237V.
24. James Cox, Las Cruces, New Mexico, Court of Federal
Claims No: 13-0238V.
25. Chanel and Paul A. Monroe on behalf of Angelina
Monroe, Las Vegas, Nevada, Court of Federal Claims No:
13-0239V.
26. Noteel Koss, Houston, Texas, Court of Federal Claims
No: 13-0240V.
27. Tamika M. Kratzer on behalf of Ian M. Kratzer,
Sacramento, California, Court of Federal Claims No:
13-0243V.
28. Rosalie Peck, Boston, Massachusetts, Court of
Federal Claims No: 13-0249V. 29. Shannon Keller,
Sacramento, California, Court of Federal Claims No:
13-0250V.
30. Edwina Bradshaw, North Myrtle Beach, North Carolina,
Court of Federal Claims No: 13-0252V.
31. William and Brenda Lehann Rodriguez on behalf of
C.R., Clayton, Georgia, Court of Federal Claims No:
13-0253V.
32. Corrine K. Ibana, Kamuela, Hawaii, Court of Federal
Claims No: 13-0257V.
33. Lorel Cubano, San Juan, Puerto Rico, Court of
Federal Claims No: 13-0259V.
34. Brittany and Davey Lambert on behalf of Noah
Lambert, Memphis, Tennessee, Court of Federal Claims No:
13-0265V.
35. Scott and Caroline VanScoy on behalf of Alyssa
VanScoy, Simi Valley, California, Court of Federal
Claims No: 13-0266V.
36. Jane Sprecher, Reading, Pennsylvania, Court of
Federal Claims No: 13-0271V.
37. Georgia Murdock, Silver Spring, Maryland, Court of
Federal Claims No: 13-0273V.
38. Willie Andre Simmons, Augusta, Georgia, Court of
Federal Claims No: 13-0274V.
39. Jung Park, M.D., New York, New York, Court of
Federal Claims No: 13-0275V.
40. Allison and Steven Council on behalf of Adam
Council, Plainfield, Illinois, Court of Federal Claims
No: 13-0276V.
41. Maryann Giordano, Lindenhurst, New York, Court of
Federal Claims No: 13-0277V.
42. Laura A. Jones, Greensboro, North Carolina, Court of
Federal Claims No: 13-0279V.
43. David D. Griffin, Afghanistan, Court of Federal
Claims No: 13-0280V.
44. James Demoski, Endicott, New York, Court of Federal
Claims No: 13-0286V.
45. Christina N. Steinat, Seattle, Washington, Court of
Federal Claims No: 13-0287V.
46. Jessica L. Stone, Baraboo, Wisconsin, Court of
Federal Claims No: 13-0289V.
47. Holly Rhew, Wichita, Kansas, Court of Federal Claims
No: 13-0293V.
48. Janet DeYear, Dallas, Texas, Court of Federal Claims
No: 13-0299V.
49. Cynthia Adkins, Sarasota, Florida, Court of Federal
Claims No: 13-0295V.
50. Saurabh V. and Archana Amin on behalf of Sheaa Amin,
Linwood, New Jersey, Court of Federal Claims No:
13-0300V.
51. Juliet and Mohamed Edoo on behalf of Justin Edoo,
Miami, Florida, Court of Federal Claims No: 13-0302V.
52. James Boyer, Boston, Massachusetts, Court of Federal
Claims No: 13-0303V.
*these are from March 13,
2013 – April 30, 2013. 48 days. what is the true number
that these 52 petitions represent ? how many don’t file
claims? think about it..its scary. I wish we could see
more about these petitions..more about the injury
caused.It is impossible for a parent to make a solid
risk/benefit analysis when it comes to vaccinations.. I
don’t care what anyone may say.. vaccine injury is
downplayed and pushed aside, disease rates and risks are
over exaggerated and blasted throughout the media via
mass scare campaigns (remember those 8 measly cases of
the measles in Wales during the month of march 2013?)
..and natural and safe preventative measures and
treatments are suppressed. How are we supposed to make
an informed medical decision when it comes to our
children being injected with almost 50 doses of 16
vaccines before the age of 6?
https://www.federalregister.gov/articles/2013/05/24/2013-12347/national-vaccine-injury-compensation-program-list-of-petitions-received?utm_content=next&utm_medium=PrevNext&utm_source=Article
“In 1990, infants received a
total of 15 vaccine doses prior to their first year of
life: 3 DPT injections (9 vaccine doses), 3 polio, and 3
Hib vaccines—5 vaccine doses at 2, 4, and 6 months of
age. By 2007, the CDC recommended 26 vaccine doses for
infants: 3 DTaP, 3 polio, 3 Hib, 3 hepatitis B, 3
pneumococcal, 3 rotavirus, and 2 influenza vaccines.
While each childhood vaccine has individually undergone
clinical trials to assess safety, studies have not been
conducted to determine the safety (or efficacy) of
combining vaccines during a single physician visit as
recommended by CDC guidelines. For example, 2-, 4-, and
6-month-old infants are expected to receive vaccines for
polio, hepatitis B, diphtheria, tetanus, pertussis,
rotavirus, Haemophilus influenzae type B, and
pneumococcal, all during a single well-baby visit—even
though this combination of 8 vaccine doses was never
tested in clinical trials.
An article written by Guess,
representing a vaccine manufacturer, claimed that it is
“impractical to conduct preapproval studies of all
combinations [of vaccines] in clinical practice.”1
However, a recent study by Miller and Goldman found that
among the developed nations, infant mortality increased
with an increase in the number of vaccine doses.2
Similar associations have also been found with respect
to other serious adverse outcomes. Delong reported that
the higher the proportion of children receiving
recommended vaccinations, the higher the prevalence of
autism or speech and language impairment.3 A CDC report
on mixed exposures to chemical substances and other
stressors, including prescribed pharmaceuticals, found
that they may produce “increased or unexpected
deleterious health effects.” In addition, “exposures to
mixed stressors can produce health consequences that are
additive, synergistic, antagonistic, or can potentiate
the response expected from individual component
exposures.”4 Administering six, seven, or eight vaccine
doses to an infant during a single physician visit may
certainly be more convenient for parents—rather than
making additional trips to the doctor’s office—but
evidence of a positive association between infant
adverse reactions and the number of vaccine doses
administered confirms that vaccine safety must remain
the highest priority”
http://het.sagepub.com/content/31/10/1012.full
“Maternal transfer of
mercury to the developing embryo/fetus: is there a safe
level?”
“This study focused on standardized embryonic and fetal
Hg exposures via primary exposure to the pregnant mother
of two common Hg sources (dietary fish and parenteral
vaccines). Data demonstrated that Hg exposures,
particularly during the first trimester of pregnancy, at
well-established dose/weight ratios produced severe
damage to humans including death. . In light of research
suggestive of a mercuric risk factor for childhood
conditions such as tic disorders, cerebral palsy, and
autism, it is essential that Hg advisories account for
secondary prenatal human exposures.”
http://www.tandfonline.com/doi/full/10.1080/02772248.2012.724574
Empirical Data Confirm
Autism Symptoms Related to Aluminum and Acetaminophen
Exposure
“Autism is a condition characterized by impaired
cognitive and social skills, associated with compromised
immune function. The incidence is alarmingly on the
rise, and environmental factors are increasingly
suspected to play a role. This paper investigates word
frequency patterns in the U.S. CDC Vaccine Adverse
Events Reporting System (VAERS) database. Our results
provide strong evidence supporting a link between autism
and the aluminum in vaccines. A literature review
showing toxicity of aluminum in human physiology offers
further support. Mentions of autism in VAERS increased
steadily at the end of the last century, during a period
when mercury was being phased out, while aluminum
adjuvant burden was being increased. Using standard
log-likelihood ratio techniques, we identify several
signs and symptoms that are significantly more prevalent
in vaccine reports after 2000, including cellulitis,
seizure, depression, fatigue, pain and death, which are
also significantly associated with aluminum-containing
vaccines. We propose that children with the autism
diagnosis are especially vulnerable to toxic metals such
as aluminum and mercury due to insufficient serum
sulfate and glutathione. A strong correlation between
autism and the MMR (Measles, Mumps, Rubella) vaccine is
also observed, which may be partially explained via an
increased sensitivity to acetaminophen administered to
control fever.”
http://www.mdpi.com/1099-4300/14/11/2227
full text:
http://groups.csail.mit.edu/sls/publications/2012/entropy-14-02227.pdf
Acetaminophen use after
measles-mumps-rubella vaccination was SIGNIFICANTLY
associated with autistic disorder when considering
children 5 years of age or less, after limiting cases to
children with regression in development and when
considering only children who had post-vaccination
sequelae adjusting for age, gender, mother’s ethnicity,
and the presence of illness concurrent with
measles-mumps-rubella vaccination. Ibuprofen use after
measles-mumps-rubella vaccination was not associated
with autistic disorder. This preliminary study found
that acetaminophen use after measles-mumps-rubella
vaccination was associated with autistic disorder.
http://www.ncbi.nlm.nih.gov/pubmed/18445737
A 1% increase in vaccination
was associated with an additional 680 children having
AUT or SLI. Neither parental behavior nor access to care
affected the results, since vaccination proportions were
not significantly related (statistically) to any other
disability or to the number of pediatricians in a U.S.
state. The results suggest that although mercury has
been removed from many vaccines, other culprits may link
vaccines to autism. Further study into the relationship
between vaccines and autism is warranted”
http://www.ncbi.nlm.nih.gov/pubmed/21623535
“Furthermore, while India
has been polio-free for a year, there has been a huge
increase in non-polio acute flaccid paralysis (NPAFP).
In 2011, there were an extra 47,500 new cases of NPAFP.
Clinically indistinguishable from polio paralysis but
twice as deadly, the incidence of NPAFP was directly
proportional to doses of oral polio received. Though
this data was collected within the polio surveillance
system, it was not investigated.”
http://www.ncbi.nlm.nih.gov/pubmed/22591873
Detection of fecal shedding
of rotavirus vaccine in infants following their first
dose of pentavalent rotavirus vaccine. (and how they
blame everything on kids that are not vaccinated is
beyond me! These vaccines are helping to keep diseases
in circulation..)
Studies on rotavirus vaccine shedding and its potential
transmission within households including
immunocompromised individuals are needed to better
define the potential risks and benefits of vaccination.
We examined fecal shedding of pentavalent rotavirus
vaccine (RV5) for 9 days following the first dose of
vaccine in infants between 6 and 12 weeks of age.
Rotavirus antigen was detected by enzyme immunoassay
(EIA), and vaccine-type rotavirus was identified by
nucleotide sequencing based on genetic relatedness to
the RV5 VP6 gene. Stool from 22 (21.4%) of 103 children
contained rotavirus antigen-positive specimens on ≥ 1
post-vaccination days. Rotavirus antigen was detected as
early as post-vaccination day 3 and as late as day 9,
with peak numbers of shedding on post-vaccination days 6
through 8. Vaccine-type rotavirus was detected in all 50
antigen-positive specimens and 8 of 8 antigen-negative
specimens. Nine (75%) of 12 EIA-positive and 1
EIA-negative samples tested culture-positive for
vaccine-type rotavirus. Fecal shedding of rotavirus
vaccine virus after the first dose of RV5 occurred over
a wide range of post-vaccination days not previously
studied. These findings will help better define the
potential for horizontal transmission of vaccine virus
among immunocompromised household contacts of vaccinated
infants for future studies
http://www.ncbi.nlm.nih.gov/pubmed/21477676
“Effectiveness of trivalent
inactivated influenza vaccine in influenza-related
hospitalization in children: a case-control study.”
“Using the Cochran-Mantel-Haenszel test for asthma
status stratification, there was a significant
association between hospitalization in asthmatic
subjects and TIV (p = 0.001). TIV did not provide any
protection against hospitalization in pediatric
subjects, especially children with asthma. On the
contrary, we found a threefold increased risk of
hospitalization in subjects who did get the TIV vaccine.
This may be a reflection not only of vaccine
effectiveness but also the population of children who
are more likely to get the vaccine.”
http://www.ncbi.nlm.nih.gov/pubmed/22525386
The odds of having a history
of asthma was twice as great among vaccinated subjects
than among unvaccinated subjects (adjusted odds ratio,
2.00; 95% confidence interval, 0.59 to 6.74). The odds
of having had any allergy-related respiratory symptom in
the past 12 months was 63% greater among vaccinated
subjects than unvaccinated subjects (adjusted odds
ratio, 1.63; 95% confidence interval, 1.05 to 2.54). The
associations between vaccination and subsequent
allergies and symptoms were greatest among children aged
5 through 10 years.
DTP or tetanus vaccination
appears to increase the risk of allergies and related
respiratory symptoms in children and adolescents.
Although it is unlikely that these results are entirely
because of any sources of bias, the small number of
unvaccinated subjects and the study design limit our
ability to make firm causal inferences about the true
magnitude of effect.
http://www.ncbi.nlm.nih.gov/pubmed/10714532
Four to 12 days post 12
month vaccination, children had a 1.33 (1.29–1.38)
increased relative incidence of the combined endpoint
compared to the control period, or at least one event
during the risk interval for every 168 children
vaccinated. Ten to 12 days post 18 month vaccination,
the relative incidence was 1.25 (95%, 1.17–1.33) which
represented at least one excess event for every 730
children vaccinated. The primary reason for increased
events was statistically significant elevations in
emergency room visits following all vaccinations. There
were non-significant increases in hospital admissions.
There were an additional 20 febrile seizures for every
100,000 vaccinated at 12 months.
Conclusions
There are significantly elevated risks of primarily
emergency room visits approximately one to two weeks
following 12 and 18 month vaccination. Future studies
should examine whether these events could be predicted
or prevented
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236196/
“Administration of
thimerosal to infant rats increases overflow of
glutamate and aspartate in the prefrontal cortex:
protective role of dehydroepiandrosterone sulfate. “
In summary, the present
study documents that exposure of infant rats to THIM
perturbs the balance between excitatory and inhibitory
amino acids in the brain, shifting it toward excessive
neuroexcitation. Despite of intrinsic limitations,
present findings have important clinical implications,
as they provide a plausible mechanism, whereby THIM
exerts neurotoxic effects in the brain. It is likely
that this mercurial—still present in pediatric vaccines
in many countries—causes a similar disturbance of
excitatory and inhibitory neurotransmitters in the
brains of human infants, leading to neurotoxicity,
encephalopaties, and in consequence to
neurodevelopmental disorders, including autism..*On the
whole, the current study provides further empirical
evidence that exposure to THIM leads to neurotoxic
changes in the developing brain, arguing for urgent and
permanent removal of this preservative from all vaccines
for children (and adults) since effective, less toxic
and less costly alternatives are available. The stubborn
insistence of some vaccine manufacturers and health
agencies on continuation of use of this proven
neurotoxin in vaccines is testimony of their disregard
for both the health of young generations and for the
environment.*A
http://www.ncbi.nlm.nih.gov/pubmed/22015977
“Thus vaccination DOES NOT
account for the impressive declines in mortality seen in
the first half of the century”
http://pediatrics.aappublications.org/content/106/6/1307.abstract
Thimerosal, an
organomercurial added as a preservative to some vaccines,
is a suspected iatrogenic factor, possibly contributing
to paediatric neurodevelopmental disorders including
autism. We examined the effects of early postnatal
administration of thimerosal (four i.m. injections, 12
or 240 μg THIM-Hg/kg, on postnatal days 7, 9, 11 and 15)
on brain pathology in Wistar rats. Numerous
neuropathological changes were observed in young adult
rats which were treated postnatally with thimerosal.
They included: ischaemic degeneration of neurons and
“dark” neurons in the prefrontal and temporal cortex,
the hippocampus and the cerebellum, pathological changes
of the blood vessels in the temporal cortex, diminished
synaptophysin reaction in the hippocampus, atrophy of
astroglia in the hippocampus and cerebellum, and
positive caspase-3 reaction in Bergmann astroglia. These
findings document neurotoxic effects of thimerosal, at
doses equivalent to those used in infant vaccines or
higher, in developing rat brain, suggesting likely
involvement of this mercurial in neurodevelopmental
disorders.
http://www.ncbi.nlm.nih.gov/pubmed/21225508
And it’s the unvaccinated
that are spreading pertussis?
“Despite widespread vaccination, whooping cough
incidence is on the rise worldwide, making it the only
vaccine-preventable disease associated with increasing
deaths in the United States. Although this disease is
most often attributed to Bordetella pertussis infection,
it is also caused by the closely related pathogen, B.
parapertussis. However, B. pertussis has remained the
center of attention, whereas B. parapertussis has been
greatly overlooked in the development of whooping cough
vaccines.
Vaccination led to a 40-fold
enhancement of B. parapertussis colonization in the
lungs of mice.. these data suggest that the vaccine may
be contributing to the observed rise in whooping cough
incidence over the last decade by promoting B.
parapertussis infection.”
http://www.cidd.psu.edu/research/synopses/acellular-vaccine-enhancement-b.-parapertussis
Despite widespread childhood
vaccination against Bordetella pertussis, disease
remains prevalent. It has been suggested that acellular
vaccine may be less effective than previously believed.
During a large outbreak, we examined the incidence of
pertussis and effectiveness of vaccination in a
well-vaccinated, well-defined community.. Our data
suggests that the current schedule of acellular
pertussis vaccine doses is insufficient to prevent
outbreaks of pertussis.
http://cid.oxfordjournals.org/content/early/2012/03/13/cid.cis287.short
In the last 3 decades, there
has been an unexplained increase in the prevalence of
asthma and hay fever.
OBJECTIVE:
We sought to determine whether there is an association
between childhood vaccination and atopic diseases, and
we assessed the self-reported prevalence of atopic
diseases in a population that included a large number of
families not vaccinating their children.
RESULTS:
The data included 515 never vaccinated, 423 partially
vaccinated, and 239 completely vaccinated children. In
multiple regression analyses there were significant ( P
< .0005) and dose-dependent negative relationships
between vaccination refusal and self-reported asthma or
hay fever only in children with no family history of the
condition and, for asthma, in children with no exposure
to antibiotics during infancy. Vaccination refusal was
also significantly ( P < .005) and negatively associated
with self-reported eczema and current wheeze. A
sensitivity analysis indicated that substantial biases
would be required to overturn the observed associations.
CONCLUSION: Parents who refuse vaccinations reported
less asthma and allergies in their unvaccinated children.
Although this relationship was independent of measured
confounders, it could be due to differences in other
unmeasured lifestyle factors or systematic bias. Further
research is needed to verify these results and
investigate which exposures are driving the associations
between vaccination refusal and allergic disease.
http://www.ncbi.nlm.nih.gov/pubmed/15805992
“Unvaccinated children
tended to be white, to have a mother who was married and
had a college degree, to live in a household with an
annual income exceeding $75,000 dollars, and to have
parents who expressed concerns regarding the safety of
vaccines and indicated that medical doctors have little
influence over vaccination decisions for their children.”
http://www.ncbi.nlm.nih.gov/pubmed/15231927
Although persons often use
vaccination and immunization interchangeably in
reference to active immunization, the terms are not
synonomous because the administration of an
immunobiologic cannot be automatically equated with the
development of adequate immunity.
http://wonder.cdc.gov/wonder/prevguid/p0000348/p0000348.asp#head002000000000000
“Virus-induced autoimmunity
may play a causal role in autism. To examine the
etiologic link of viruses in this brain disorder, we
conducted a serologic study of measles virus, mumps
virus, and rubella virus. Viral antibodies were measured
by enzyme-linked immunosorbent assay in the serum of
autistic children, normal children, and siblings of
autistic children. The level of measles antibody, but
not mumps or rubella antibodies, was significantly
higher in autistic children as compared with normal
children (P = 0.003) or siblings of autistic children (P
<or= 0.0001). Furthermore, immunoblotting of measles
vaccine virus revealed that the antibody was directed
against a protein of approximately 74 kd molecular
weight. The antibody to this antigen was found in 83% of
autistic children but not in normal children or siblings
of autistic children. Thus autistic children have a
hyperimmune response to measles virus, which in the
absence of a wild type of measles infection might be a
sign of an abnormal immune reaction to the vaccine
strain or virus reactivation.
http://www.ncbi.nlm.nih.gov/pubmed/12849883
We do not vaccinate against
yellow fever in the US but this still is of importance
because it shows that things like this can and HAVE
happened.
“However, in 2001, the vaccine was found to cause a
serious, frequently fatal, multisystemic illness, called
yellow fever vaccine–associated viscerotropic disease (YEL-AVD),
which resembles the illness it was designed to prevent
(1–3). “
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3310656/
Effectiveness of Influenza
Vaccine in the Community-Dwelling Elderly
“Most high-risk medical conditions that were measured
were more prevalent among vaccinated than among
unvaccinated persons.”
http://jama.jamanetwork.com/article.aspx?articleid=189023
”The aim of this study was
to compare the number of inactivated-influenza vaccine–related
spontaneous abortion and stillbirth (SB) reports in the
Vaccine Adverse Event Reporting System (VAERS) database
during three consecutive flu seasons beginning 2008/2009
and assess the relative fetal death reports associated
with the two-vaccine 2009/2010 season. The VAERS
database was searched for reports of fetal demise
following administration of the influenza vaccine/vaccines
to pregnant women.. reporting bias was too low to
explain the magnitude increase in fetal-demise reporting
rates in the VAERS database relative to the reported
annual trends. Thus, a synergistic fetal toxicity likely
resulted from the administration of both the pandemic
(A-H1N1) and seasonal influenza vaccines during the
2009/2010 season.”
http://het.sagepub.com/content/early/2012/09/12/0960327112455067.abstract
Hepatitis B vaccine might be
followed by various rheumatic conditions and might
trigger the onset of underlying inflammatory or
autoimmune rheumatic diseases.. Further epidemiological
studies are needed to establish whether hepatitis B
vaccination is associated or not with an incidence of
rheumatic disorders higher than normal. A few cases of
onset or reactivation of SLE after vaccination against
hepatitis B have been described. The onset of symptoms
occurred within 5 days–1 month after the immunization.
Two patients had a lupus nephritis (associated in one
with fever and arthralgia), one patient had
pericarditis, one had thrombocytopenic purpura.. We
observed four patients with myalgia and polyarthralgia,
and, in three of them, fatigue following hepatitis B
vaccination. These manifestations can be connected to
the chronic fatigue syndrome. A few years ago, an
independent working group agreed that there was no
evidence of a cause–effect relationship between
hepatitis B vaccine and chronic fatigue syndrome [37].
However, the number of patients followed up may have
been too small to detect a slight increase in the
relative risk.
Various other conditions following hepatitis B
vaccination have been described. They include erythema
nodosum and polyarthritis [21], erythema nodosum with
arthralgia and Takayasu’s arteritis [38], vasculitis
[39–41], polyarthritis associated with hypercalcaemia
and lytic bone lesions [29].
http://rheumatology.oxfordjournals.org/content/38/10/978.long
“Autoimmunity to the central
nervous system (CNS), especially to myelin basic protein
(MBP), may play a causal role in autism, a
neurodevelopmental disorder. Because many autistic
children harbor elevated levels of measles antibodies,
we conducted a serological study of
measles-mumps-rubella (MMR) and MBP autoantibodies.
Using serum samples of 125 autistic children and 92
control children, antibodies were assayed by ELISA or
immunoblotting methods. ELISA analysis showed a
significant increase in the level of MMR antibodies in
autistic children. Immunoblotting analysis revealed the
presence of an unusual MMR antibody in 75 of 125 (60%)
autistic sera but not in control sera. This antibody
specifically detected a protein of 73-75 kD of MMR. This
protein band, as analyzed with monoclonal anti bodies,
was immunopositive for measles hemagglutinin (HA)
protein but not for measles nucleoprotein and rubella or
mumps viral proteins. Thus the MMR antibody in autistic
sera detected measles HA protein, which is unique to the
measles subunit of the vaccine. Furthermore, over 90% of
MMR antibody-positive autistic sera were also positive
for MBP autoantibodies, suggesting a strong association
between MMR and CNS autoimmunity in autism. Stemming
from this evidence, we suggest that an inappropriate
antibody response to MMR, specifically the measles
component thereof, might be related to pathogenesis of
autism.”
http://www.ncbi.nlm.nih.gov/pubmed/12145534
http://vran.org/wp-content/documents/VRAN-Abnormal%20Measles-Mumps-Rubella-Antibodies-CNS-Autoimmunity-Children-Autism-Singh-Lin-Newell-Nelson.pdf
“Autoimmune hazards of
hepatitis B vaccine”
“According to Hippocratic tradition, the safety level of
a preventive medicine must be very high, as it is aimed
at protecting people against diseases that they may not
contract. This paper points out that information on the
safety of hepatitis B vaccine (HBV) is biased as
compared to classical requirements of evidence-based
medicine (EBM), as exemplified by a documented
selectivity in the presentation or even publication of
available clinical or epidemiological data. Then, a
review is made of data suggesting that HBV is remarkable
by the frequency, the severity and the variety of its
complications, some of them probably related to a
mechanism of molecular mimicry leading to demyelinating
diseases, and the others reproducing the spectrum of
non-hepatic manifestations of natural hepatitis B. To be
explained, this unusual spectrum of toxicity requires
additional investigations based upon complete release of
available data.
-More research is necessary and there is a need that the
scientific community exerts pressure on health
authorities to obtain that all existing data become
available for peer-reviewed debate.
-There is an impressive convergence of data given
credibility to a potential of this vaccine to induce
severe and irreversible central demyelinating disorders.
-A number of clinical or epidemiological data on the
safety hepatitis B vaccine (HBV) have not been published
and do not seem to be.
-Modern vaccine research and development does not comply
with basic requirements of evidence based medicine (EBM).”
http://www.ncbi.nlm.nih.gov/pubmed/15722255
FULL TEXT
http://sanevax.org/wp-content/uploads/2011/02/autoimmune-hazards-hepB-vaccine1.pdf
“We find that ethylmercury
not only inhibits mitochondrial respiration leading to a
drop in the steady state membrane potential, but also
concurrent with these phenomena increases the formation
of superoxide, hydrogen peroxide, and Fenton/Haber-Weiss
generated hydroxyl radical. These oxidants increase the
levels of cellular aldehyde/ketones. Additionally, we
find a five-fold increase in the levels of oxidant
damaged mitochondrial DNA bases and increases in the
levels of mtDNA nicks and blunt-ended breaks.. These
mitochondria appear to have undergone a permeability
transition, an observation supported by the five-fold
increase in Caspase-3 activity observed after Thimerosal
treatment.”
*the next time someone says that ethylmercury is ok for
children ask them to read this article.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395253/
The main route of Al
excretion is the urine; therefore, subjects with kidney
malfunction or immature kidney, such as nephropathy
patients or neonates, might experience toxic
accumulation of Al in the body [12]. Infant formula is
the primary food source for bottle-fed neonates. The
study of Yuan et al reviewed several other studies and
reported that most commercial infant formulas contained
higher Al (6.5 μM to 87 μM) than human breast milk (0.2
μM to 1.7 μM) [12]. Infants display rapid growth and
their brain-blood-barrier, detoxification system
(liver), and excretory system (kidney) are not
well-developed [13,14]. Aluminum can cross the
blood-brain barrier and accumulate in glial and neural
cells [15]. Thus, high intake of Al-containing formula
might cause accumulation of Al in the neonatal brain,
interfering with appropriate development.
In previous studies, exposure to excess dietary Al
during gestation and lactation periods had no toxic
effects on the mother, but resulted in persistent
neurobehavioral deficits in the pups, such as defects in
the sensory motor reflexes, locomotor activity, learning
capability, and cognitive behavior [16,17]. These
behavioral studies, therefore, suggested that Al
exposure might cause developmental changes in neonatal
brain. Until recently, a marker with which to
effectively detect neonatal brain development was
lacking. The group’s previous study with Al treatment in
neonatal rat hippocampal neurons at concentrations of 37
μM and 74 μM for 14 days significantly reduced NMDAR
(N-methyl-D-aspartate receptor) expression which was
used as a marker of brain development. This suggested
that Al exposure might influence the development of
hippocampal neurons in neonatal rats.
http://www.jbiomedsci.com/content/19/1/51
The future of measles in
highly immunized population. A modeling approach
However, despite short-term success in eliminating the
disease, long-range projections demonstrate that the
proportion of susceptibles in the year 2050 may be
greater than in the prevaccine era. Present vaccine
technology and public health policy must be altered to
deal with this eventuality.
http://www.ncbi.nlm.nih.gov/pubmed/6741921
Summary
In conclusion, by apparently prioritizing vaccination
policy over vaccine safety, the JCVI, the DH and the
Committee on Safety of Medicines (CSM) may have shown a
disregard for the safety of children. Through selective
data reporting, the JCVI in conjunction with the DH, has
promulgated information relating to vaccine safety that
may be inaccurate and potentially misleading,
therebymaking it impossible for the parents to make a
fully informed consent regarding vaccination.Furthermore,
by 1) apparently misleading patients about the true
risks of adverse reactions as togain their consent for
the administration of the treatment and 2) seemingly
siding with vaccinemanufacturers rather than public
health interests, the JCVI and the CSM appear to have
signally failed their fiduciary duty to protect
individuals from vaccines of questionable safety. If
these provisional conclusions are indeed correct, then
the information presented here may help us in
understanding the UK government’s and the JCVI’s
official position on vaccine damage, that is, one of
persistent denial.
http://www.ecomed.org.uk/wp-content/uploads/2011/09/3-tomljenovic.pdf
“One way forward that
appears to be favoured by most in the medical
establishment is to continue to add more and more
vaccines indiscriminately to the immunisation schedule
in ever larger combinations. Just to question this
policy is to be accused of putting children’s lives at
risk and of being “anti-vaccine”. I have been called
“anti-vaccine” even though I actually run a children’s
immunisation clinic!
The government can’t bear any suggestion of lack of
safety of vaccines. They will not even discuss it. I
think they have a policy of suppression of any
discussion on safety. This was said by a leading vaccine
expert with the Cochrane Collaboration, a widely
respected international not-for-profit and independent
organisation, dedicated to making up-to-date and
accurate information about the effects of health care
readily available worldwide.
I would advocate another way forward: a more cautious
approach incorporating honesty about the true benefits
and risks of vaccination to enable parents to make a
genuinely informed choice. I would like to see an
environment in which parents are able to have a rational
discussion without bullying, patronising, condescension
and being accused of putting their child at risk.”
“Vaccine, Atopy and Allergy:
Problems and Solutions”
http://www.ecomed.org.uk/wp-content/uploads/2011/09/2-halvorsen.pdf
Prior to the introduction of vaccines, children who were
absent at a village examination had the same mortality
as children who were present. During 1984-1987, children
receiving DTP at 2-8 months of age had higher mortality
over the next 6 months, the mortality rate ratio (MR)
being 1.92 (95% CI: 1.04, 3.52) compared with
DTP-unvaccinated children, adjusting for age, sex,
season, period, BCG, and region. The MR was 1.81 (95% CI:
0.95, 3.45) for the first dose of DTP and 4.36 (95% CI:
1.28, 14.9) for the second and third dose. BCG was
associated with slightly lower mortality (MR = 0.63, 95%
CI: 0.30, 1.33), the MR for DTP and BCG being
significantly inversed. Following subsequent visits and
further vaccinations with DTP and measles vaccine, there
was no difference in vaccination coverage and subsequent
mortality between the DTP-vaccinated group and the
initially DTP-unvaccinated group (MR = 1.06, 95% CI:
0.78, 1.44).
CONCLUSIONS:
In low-income countries with high mortality, DTP as the
last vaccine received may be associated with slightly
increased mortality. Since the pattern was inversed for
BCG, the effect is unlikely to be due to higher-risk
children having received vaccination. The role of DTP in
high mortality areas needs to be clarified.
http://www.ncbi.nlm.nih.gov/pubmed/15082643
Aluminium is the most widely
distributed metal in the environment and is extensively
used in daily life that provides easy exposure to human
beings. The exposure to this toxic metal occurs through
air, food and water. However, there is no known
physiological role for aluminium within the body and
hence this metal may produce adverse physiological
effects. Chronic exposure of animals to aluminium is
associated with behavioural, neuropathological and
neurochemical changes. Among them, deficits of learning
and behavioural functions are most evident. Some
epidemiological studies have shown poor performance in
cognitive tests and a higher abundance of neurological
symptoms for workers occupationally exposed to aluminium.
http://www.ncbi.nlm.nih.gov/pubmed/19568732
High blood mercury level was
associated with ADHD. Whether the relationship is causal
requires further studies.
http://www.ncbi.nlm.nih.gov/pubmed/?term=17177150
Attention-deficit hyperactivity disorder and blood
mercury level: a case-control study in Chinese children.
CONCLUSION: High blood mercury level was associated
with ADHD. Whether the relationship is causal requires
further studies.
Conflicts of interest ? Wow..this is from a study that
concluded that boys need the HPV vaccine..a vaccine for
cervical cancer. You can find this info at the bottom of
the article.
“Supported by Merck and by grants (M01-RR-00079 and UL1
RR024131, to Dr. Palefsky) from the National Center for
Research Resources and by a grant (RO1 CA098803, to Dr.
Giuliano) from the National Institutes of Health.
Drs. Giuliano, Ferris,
Moreira, Penny, and Palefsky report receiving grant
support from Merck, either personally or through their
institution; Dr. Penny reports receiving grant support
from GlaxoSmithKline; Dr. Goldstone reports receiving
grant support from Qiagen; Drs. Giuliano, Ferris,
Moreira, Hillman, and Chang report receiving speaking
fees or fees for board membership from Merck; Dr. Moi
reports that his institution has received funding from
Merck; Dr. Penny reports having stock or stock options
in AstraZeneca; Dr. Palefsky reports receiving
consulting fees from GlaxoSmithKline; Drs. Giuliano,
Palefsky, Goldstone, Moreira, Moi, and Chang report
receiving travel reimbursement from Merck; Dr. Bryan
reports having an approved, filed, or pending patent
related to subject matter discussed in this article; and
Dr. Bryan, Dr. Marshall, Dr. Vuocolo, Dr. Barr, Dr.
Haupt, Mr. Radley, and Dr. Guris are employees of Merck
and own Merck stock or stock options.”
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495065/
http://www.meerwetenoverfreek.nl/images/stories/Tomljenovic_Shaw-CMC-published.pdf
Abstract: Aluminum is an experimentally demonstrated
neurotoxin and the most commonly used vaccine adjuvant.
Despite almost 90 years of widespread use of aluminum
adjuvants, medical science’s understanding about their
mechanisms of action is still remarkably poor. There is
also a concerning scarcity of data on toxicology and
pharmacokinetics of these compounds. In spite of this,
the notion that aluminum in vaccines is safe appears to
be widely accepted. Experimental research, however,
clearly shows that aluminum adjuvants have a potential
to induce serious immunological disorders in humans. In
particular, aluminum in adjuvant form carries a risk for
autoimmunity, long-term brain inflammation and
associated neurological complications and may thus have
profound and widespread adverse health consequences. In
our opinion, the possibility that vaccine benefits may
have been overrated and the risk of potential adverse
effects underestimated, has not been rigorously
evaluated in the medical and scientific community. We
hope that the present paper will provide a framework for
a much needed and long overdue assessment of this highly
contentious medical issue.
High reprint orders in medical journals and
pharmaceutical industry funding: case-control study
http://www.bmj.com/content/344/bmj.e4212
Conflicts of interest ?
Wow..this is from a study that concluded that boys need
the HPV vaccine..a vaccine for cervical cancer. You can
find this info at the bottom of the article.
about the author: “ RS was an editor for the BMJ for 25
years. For the last 13 of those years, he was the editor
and chief executive of the BMJ Publishing Group,
responsible for the profits of not only the BMJ but of
the whole group, which published some 25 other journals.
He stepped down in July 2004. He is now a member of the
board of the Public Library of Science, a position for
which he is not paid.”
“Journals have devolved into
information laundering operations for the pharmaceutical
industry”, wrote Richard Horton, editor of the Lancet,
in March 2004 [1]. In the same year, Marcia Angell,
former editor of the New England Journal of Medicine,
lambasted the industry for becoming “primarily a
marketing machine” and co-opting “every institution that
might stand in its way” [2]. Medical journals were
conspicuously absent from her list of co-opted
institutions, but she and Horton are not the only
editors who have become increasingly queasy about the
power and influence of the industry. Jerry Kassirer,
another former editor of the New England Journal of
Medicine, argues that the industry has deflected the
moral compasses of many physicians [3], and the editors
of PLoS Medicine have declared that they will not become
“part of the cycle of dependency…between journals and
the pharmaceutical industry” [4]. Something is clearly
up.
The Problem: Less to Do with
Advertising, More to Do with Sponsored Trials
The most conspicuous example
of medical journals’ dependence on the pharmaceutical
industry is the substantial income from advertising, but
this is, I suggest, the least corrupting form of
dependence. The advertisements may often be misleading
[5,6] and the profits worth millions, but the
advertisements are there for all to see and criticise.
Doctors may not be as uninfluenced by the advertisements
as they would like to believe, but in every sphere, the
public is used to discounting the claims of advertisers.
The much bigger problem lies
with the original studies, particularly the clinical
trials, published by journals. Far from discounting
these, readers see randomised controlled trials as one
of the highest forms of evidence. A large trial
published in a major journal has the journal’s stamp of
approval (unlike the advertising), will be distributed
around the world, and may well receive global media
coverage, particularly if promoted simultaneously by
press releases from both the journal and the expensive
public-relations firm hired by the pharmaceutical
company that sponsored the trial. For a drug company, a
favourable trial is worth thousands of pages of
advertising, which is why a company will sometimes spend
upwards of a million dollars on reprints of the trial
for worldwide distribution. The doctors receiving the
reprints may not read them, but they will be impressed
by the name of the journal from which they come. The
quality of the journal will bless the quality of the
drug.
Fortunately from the point
of view of the companies funding these trials—but
unfortunately for the credibility of the journals who
publish them—these trials rarely produce results that
are unfavourable to the companies’ products [7,8]. Paula
Rochon and others examined in 1994 all the trials funded
by manufacturers of nonsteroidal anti-inflammatory drugs
for arthritis that they could find [7]. They found 56
trials, and not one of the published trials presented
results that were unfavourable to the company that
sponsored the trial. Every trial showed the company’s
drug to be as good as or better than the comparison
treatment.
By 2003 it was possible to
do a systematic review of 30 studies comparing the
outcomes of studies funded by the pharmaceutical
industry with those of studies funded from other sources
[8]. Some 16 of the studies looked at clinical trials or
meta-analyses, and 13 had outcomes favourable to the
sponsoring companies. Overall, studies funded by a
company were four times more likely to have results
favourable to the company than studies funded from other
sources. In the case of the five studies that looked at
economic evaluations, the results were favourable to the
sponsoring company in every case.
The evidence is strong that
companies are getting the results they want, and this is
especially worrisome because between two-thirds and
three-quarters of the trials published in the major
journals—Annals of Internal Medicine, JAMA, Lancet, and
New England Journal of Medicine—are funded by the
industry [9]. For the BMJ, it’s only one-third—partly,
perhaps, because the journal has less influence than the
others in North America, which is responsible for half
of all the revenue of drug companies, and partly because
the journal publishes more cluster-randomised trials
(which are usually not drug trials) [9].
Why Do Pharmaceutical
Companies Get the Results They Want?
Why are pharmaceutical
companies getting the results they want? Why are the
peer-review systems of journals not noticing what seem
to be biased results? The systematic review of 2003
looked at the technical quality of the studies funded by
the industry and found that it was as good—and often
better—than that of studies funded by others [8]. This
is not surprising as the companies have huge resources
and are very familiar with conducting trials to the
highest standards.
The companies seem to get
the results they want not by fiddling the results, which
would be far too crude and possibly detectable by peer
review, but rather by asking the “right” questions—and
there are many ways to do this [10]. Some of the methods
for achieving favourable results are listed in the
Sidebar, but there are many ways to hugely increase the
chance of producing favourable results, and there are
many hired guns who will think up new ways and stay one
jump ahead of peer reviewers.
Then, various publishing
strategies are available to ensure maximum exposure of
positive results. Companies have resorted to trying to
suppress negative studies [11,12], but this is a crude
strategy—and one that should rarely be necessary if the
company is asking the “right” questions. A much better
strategy is to publish positive results more than once,
often in supplements to journals, which are highly
profitable to the publishers and shown to be of dubious
quality [13,14]. Companies will usually conduct
multicentre trials, and there is huge scope for
publishing different results from different centres at
different times in different journals. It’s also
possible to combine the results from different centres
in multiple combinations.
These strategies have been
exposed in the cases of risperidone [15] and odansetron
[16], but it’s a huge amount of work to discover how
many trials are truly independent and how many are
simply the same results being published more than once.
And usually it’s impossible to tell from the published
studies: it’s necessary to go back to the authors and
get data on individual patients.
Peer Review Doesn’t Solve
the Problem
Journal editors are becoming
increasingly aware of how they are being manipulated and
are fighting back [17,18], but I must confess that it
took me almost a quarter of a century editing for the
BMJ to wake up to what was happening. Editors work by
considering the studies submitted to them. They ask the
authors to send them any related studies, but editors
have no other mechanism to know what other unpublished
studies exist. It’s hard even to know about related
studies that are published, and it may be impossible to
tell that studies are describing results from some of
the same patients. Editors may thus be peer reviewing
one piece of a gigantic and clever marketing jigsaw—and
the piece they have is likely to be of high technical
quality. It will probably pass peer review, a process
that research has anyway shown to be an ineffective
lottery prone to bias and abuse [19].
Furthermore, the editors are
likely to favour randomised trials. Many journals
publish few such trials and would like to publish more:
they are, as I’ve said, a superior form of evidence. The
trials are also likely to be clinically interesting.
Other reasons for publishing are less worthy. Publishers
know that pharmaceutical companies will often purchase
thousands of dollars’ worth of reprints, and the profit
margin on reprints is likely to be 70%. Editors, too,
know that publishing such studies is highly profitable,
and editors are increasingly responsible for the budgets
of their journals and for producing a profit for the
owners. Many owners—including academic societies—depend
on profits from their journals. An editor may thus face
a frighteningly stark conflict of interest: publish a
trial that will bring US$100 000 of profit or meet the
end-of-year budget by firing an editor.
Journals Should Critique
Trials, Not Publish Them
How might we prevent
journals from being an extension of the marketing arm of
pharmaceutical companies in publishing trials that
favour their products? Editors can review protocols,
insist on trials being registered, demand that the role
of sponsors be made transparent, and decline to publish
trials unless researchers control the decision to
publish [17,18]. I doubt, however, that these steps will
make much difference. Something more fundamental is
needed.
Firstly, we need more public
funding of trials, particularly of large head-to-head
trials of all the treatments available for treating a
condition. Secondly, journals should perhaps stop
publishing trials. Instead, the protocols and results
should be made available on regulated Web sites. Only
such a radical step, I think, will stop journals from
being beholden to companies. Instead of publishing
trials, journals could concentrate on critically
describing them.
Examples of Methods for
Pharmaceutical Companies to Get the Results They Want
from Clinical Trials
- Conduct a trial of your drug against a treatment known
to be inferior.
- Trial your drugs against too low a dose of a
competitor drug.
- Conduct a trial of your drug against too high a dose
of a competitor drug (making your drug seem less toxic).
- Conduct trials that are too small to show differences
from competitor drugs.
- Use multiple endpoints in the trial and select for
publication those that give favourable results.
- Do multicentre trials and select for publication
results from centres that are favourable.
- Conduct subgroup analyses and select for publication
those that are favourable.
Present results that are
most likely to impress—for example, reduction in
relative rather than absolute risk”
http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.0020138
Failure of the excretory
system influences elimination of heavy metals and
facilitates their accumulation and subsequent
manifestation as neurotoxins: the long-term consequences
of which would lead to neurodegeneration, cognitive and
developmental problems. It may also influence regulation
of neural hyperthermia. This article explores the issues
and concludes that sensory dysfunction and systemic
failure, manifested as autism, is the inevitable
consequence arising from subtle DNA alteration and
consequently from the overuse of vaccines.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364648/
The article in the Journal
of Immunotoxicology is entitled “Theoretical aspects of
autism: Causes–A review.” The author is Helen Ratajczak,
surprisingly herself a former senior scientist at a
pharmaceutical firm. Ratajczak did what nobody else
apparently has bothered to do: she reviewed the body of
published science since autism was first described in
1943. Not just one theory suggested by research such as
the role of MMR shots, or the mercury preservative
thimerosal; but all of them.
Ratajczak’s article states,
in part, that “Documented causes of autism include
genetic mutations and/or deletions, viral infections,
and encephalitis [brain damage] following vaccination
[emphasis added]. Therefore, autism is the result of
genetic defects and/or inflammation of the brain.”
The article goes on to
discuss many potential vaccine-related culprits,
including the increasing number of vaccines given in a
short period of time. “What I have published is highly
concentrated on hypersensitivity, Ratajczak told us in
an interview, “the body’s immune system being thrown out
of balance.”
Ratajczak also looks at a
factor that hasn’t been widely discussed: human DNA
contained in vaccines. That’s right, human DNA.
Ratajczak reports that about the same time vaccine
makers took most thimerosal out of most vaccines (with
the exception of flu shots which still widely contain
thimerosal), they began making some vaccines using human
tissue. Ratajczak says human tissue is currently used in
23 vaccines. She discusses the increase in autism
incidences corresponding with the introduction of human
DNA to MMR vaccine, and suggests the two could be
linked. Ratajczak also says an additional increased
spike in autism occurred in 1995 when chicken pox
vaccine was grown in human fetal tissue.
Why could human DNA
potentially cause brain damage? The way Ratajczak
explained it to me: “Because it’s human DNA and
recipients are humans, there’s homologous recombinaltion
tiniker. That DNA is incorporated into the host DNA. Now
it’s changed, altered self and body kills it. Where is
this most expressed? The neurons of the brain. Now you
have body killing the brain cells and it’s an ongoing
inflammation. It doesn’t stop, it continues through the
life of that individual.”
Dr. Strom said he was
unaware that human DNA was contained in vaccines but
told us, “It does not matter…Even if human DNA were then
found in vaccines, it does not mean that they cause
autism.” Ratajczak agrees that nobody has proven DNA
causes autism; but argues nobody has shown the opposite,
and scientifically, the case is still open.
A number of independent
scientists have said they’ve been subjected to
orchestrated campaigns to discredit them when their
research exposed vaccine safety issues, especially if it
veered into the topic of autism. We asked Ratajczak how
she came to research the controversial topic. She told
us that for years while working in the pharmaceutical
industry, she was restricted as to what she was allowed
to publish. “I’m retired now,” she told CBS News. “I can
write what I want.”
http://www.cbsnews.cm/8301-31727_162-20049118-10391695.html
great summary:
http://danmurphydc.com/wordpress/wp-content/uploads/2011/01/AR-10-12-rata-AUTISM-VACCINE.pdf
abstract:
http://informahealthcare.com/doi/abs/10.3109/1547691X.2010.545086
“Vaccines are not subject to
double blind clinical trials despite the evidence of
vaccine-drug interactions and perhaps also of
vaccine-vaccine interactions.”
“Whooping cough is becoming
increasingly prevalent[168–170]. Although claimed to be
88 per cent effective among children of 7-18 months,
during a nationwide epidemic of whooping cough in 1993,
a group of researchers discovered that 82 per cent had
completed their full complement of DPT vaccines[171].
Others have commented that the whooping cough vaccine is
only to be 36% effective[109].
Many studies show that the
measles vaccine isn’t completely effective[172–175] and
that a significant proportion of those infected in
measles outbreaks (>60%) had been vaccinated. There is
also a lack of consensus concerning the effectiveness of
whole or acellular vaccines, each having their own
side-effects and effectiveness[176] e.g. vaccine
efficacy was estimated at 75.4% for an acellular 5
component vaccine, 42.4% for an acellular two component
vaccine and 28% for a whole cell DTP vaccine[177]. The
whole-cell vaccine was associated with different levels
of side-effects including significantly higher rates of
crying, cyanosis, fever, and local reactions than the
other three vaccines.”
“Aluminum also shares common
mechanisms with mercury e.g. it interferes with cellular
and metabolic processes in the nervous system. Children
given the recommended vaccinations are injected with
nearly 5 mg of aluminum by the time they are just 1.5
years old, almost 6 times the safe level. Furthermore
the nature of the Aluminium affects the prevailing blood
levels and is also increasingly implicated, through
their use as vaccine adjuvants, in autism[252].”
“Where is the proof that
vaccines are safe? The argument has never been that they
are completely safe but that the consequences are less
than having the disease. Now it is illustrated that the
consequences of intensive vaccination schedules pose a
greater risk than could ever have been imagined. This
leads to the evolution of new viral strains, an
unsurprising development when the environment to which
it is exposed is being altered by new proteins,
structural variants and ALTERED DNA.”
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364648/
over 600 peer reviewed
citations that show a link between vaccines and autism.
How is it possible that the majority of society thinks
that we are crazy ..? The studies that they based this
belief on were funded by companies and affliated with
groups that all profit because of vaccines. The saddest
part of this all is that these studies were all apart of
a strategy to make people feel this way..and it worked.
Slowly though, because of the voices that will not stop,
people are starting to hear the truth.
Warning: do not click on
this link if you are on your phone and dont want to
upload a 3 mb pdf :
http://www.tacanow.org/wp-content/uploads/2011/09/autism-studies-april-2008.pdf
the potential conflicts from
this article that, or course, shows no connection:
“Vaccines and Autism: A Tale
of Shifting Hypotheses”
“Potential conflicts of
interest.P.A.O.[ PAO is one of the authors of this
paper- Paul Offit.] is a coinventor and patent coholder
of the rotavirus vaccine Rotateq and has served on a
scientific advisory board to Merck.”
http://cid.oxfordjournals.org/content/48/4/456.full
“Repeated immunization with
antigen causes systemic autoimmunity in mice otherwise
not prone to spontaneous autoimmune diseases. Overstimulation of CD4+ T cells led to the development
of autoantibody-inducing CD4+ T (aiCD4+ T) cell which
had undergone T cell receptor (TCR) revision and was
capable of inducing autoantibodies. The aiCD4+ T cell
was induced by de novo TCR revision but not by
cross-reaction, and subsequently overstimulated CD8+ T
cells, driving them to become antigen-specific cytotoxic
T lymphocytes (CTL). These CTLs could be further matured
by antigen cross-presentation, after which they caused
autoimmune tissue injury akin to systemic lupus
erythematosus (SLE).
Conclusions/Significance
Systemic autoimmunity appears to be the inevitable
consequence of over-stimulating the host’s immune
‘system’ by repeated immunization with antigen, to the
levels that surpass system’s self-organized
criticality.”
http://www.plosone.org/article/info:doi%2F10.1371%2Fjournal.pone.0008382
This talks about aluminum
exposure from infant formula..im not sure why they never
mention aluminum exposure from vaccines. newborn rats
were injected with aluminum chloride..not sure why all
the harm done because of this and the “cause for concern”
is not ever connected to vaccines. Given the fact that a
vaccine with 250mcg of aluminum is recommended for every
1 day old baby born in this country.. and then multiple
loads of aluminum at 2,4,6 and 12-18 months and so on..its
a surprise to me that they failed to mention vaccines.
“Aluminum overload increases
oxidative stress in four functional brain areas of
neonatal rats”
Aluminum overload increases
oxidative stress (H2O2) in the hippocampus, diencephalon,
cerebellum, and brain stem in neonatal rats. (In humans,
oxidative stress is thought to be involved in the
development of cancer, Parkinson’s disease, Alzheimer’s
disease, atherosclerosis, heart failure, myocardial
infarction, fragile X syndrome, Sickle Cell Disease,lichen
planus, vitiligo, autism, and chronic fatigue syndrome)
.
“The main route of Al
excretion is the urine; therefore, subjects with kidney
malfunction or immature kidney, such as nephropathy
patients or neonates, might experience toxic
accumulation of Al in the body [12]. Infant formula is
the primary food source for bottle-fed neonates. The
study of Yuan et al reviewed several other studies and
reported that most commercial infant formulas contained
higher Al (6.5 μM to 87 μM) than human breast milk (0.2
μM to 1.7 μM) [12]. Infants display rapid growth and
their brain-blood-barrier, detoxification system
(liver), and excretory system (kidney) are not
well-developed [13,14]. Aluminum can cross the
blood-brain barrier and accumulate in glial and neural
cells [15]. Thus, high intake of Al-containing formula
might cause accumulation of Al in the neonatal brain,
interfering with appropriate development.
In previous studies,
exposure to excess dietary Al during gestation and
lactation periods had no toxic effects on the mother,
but resulted in persistent neurobehavioral deficits in
the pups, such as defects in the sensory motor reflexes,
locomotor activity, learning capability, and cognitive
behavior [16,17]. These behavioral studies, therefore,
suggested that Al exposure might cause developmental
changes in neonatal brain. Until recently, a marker with
which to effectively detect neonatal brain development
was lacking. The group’s previous study with Al
treatment in neonatal rat hippocampal neurons at
concentrations of 37 μM and 74 μM for 14 days
significantly reduced NMDAR (N-methyl-D-aspartate
receptor) expression which was used as a marker of brain
development. This suggested that Al exposure might
influence the development of hippocampal neurons in
neonatal rats [12].”
http://www.jbiomedsci.com/content/19/1/51
Lasting neuropathological
changes in rat brain after intermittent neonatal
administration of thimerosal. “These findings document
neurotoxic effects of thimerosal, at doses equivalent to
those used in infant vaccines or higher, in developing
rat brain, suggesting likely involvement of this
mercurial in neurodevelopmental disorders”
http://www.ncbi.nlm.nih.gov/pubmed/21225508
The ACIP policy
recommendation of routinely administering influenza
vaccine during pregnancy is ill-advised and unsupported
by current scientific literature, and it should be
withdrawn. Use of thimerosal during pregnancy should be
contraindicated.
adult influenza vaccines
contain an equivalent of 25 µg of mercury per dose
(Table 1). An average-sized pregnant woman receiving an
influenza vaccine will be exposed to organic mercury
that exceeds the EPA limit by a factor of 3.5 (Table 4).
The fetus could potentially receive a dose of mercury
that exceeds EPAlimits by a much larger factor.
Furthermore, fetal blood mercury concentrations have
been shown to be as much as 4.3 times the maternal
level. Alarger proportion of ethyl mercury accumulates
in fetal tissues relative to maternal tissues,
especially in the central nervous system. The
observation of a 7.8-15.7% prevalence of elevated
umbilical cord mercury in the United States, at levels
associated with loss of IQ, adds to the significance of
additional mercury exposure from prenatal vaccination.
http://www.jpands.org/vol11no2/ayoub.pdf
ive heard a lot of people
try to discredit this study, and maybe some of the
things they are saying are justified…but there is no
getting around the solid conclusion of this article.
less vaccines = less death
“The US childhood
immunization schedule requires 26 vaccine doses for
infants aged less than 1 year, the most in the world,
yet 33 nations have better IMRs. [infant mortality rate]
Using linear regression, the immunization schedules of
these 34 nations were examined.. When nations were
grouped into five different vaccine dose ranges, 98.3%
of the total variance in IMR was explained by the
unweighted linear regression model. These findings
demonstrate a counter-intuitive relationship: nations
that require more vaccine doses tend to have higher
infant mortality rates.”
[a part of the study also looks at SIDS]
“Prior to contemporary
vaccination programs, ‘Crib death’ was so infrequent
that it was not mentioned in infant mortality
statistics. In the United States, national immunization
campaigns were initiated in the 1960s when several new
vaccines were introduced and actively recommended. For
the first time in history, most US infants were required
to receive several doses of DPT, polio, measles, mumps,
and rubella vaccines.14 Shortly thereafter, in 1969,
medical certifiers presented a new medical term—sudden
infant death syndrome.”
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170075/#bibr25-0960327111407644
[this article was recently
published in the journal, Lupus. The article is
heavily-cited, and all factual claims are backed up by
citations of studies. this study can also be found on
pubmed and sage but you have to pay to see the full
text.]
“Immune challenges during
early development, including those vaccine-induced, can
lead to permanent detrimental alterations of the brain
and immune function. Experimental evidence also shows
that simultaneous administration of as little as two to
three immune adjuvants can overcome genetic resistance
to autoimmunity. In some developed countries, by the
time children are 4 to 6 years old, they will have
received a total of 126 antigenic compounds along with
high amounts of aluminum (Al) adjuvants through routine
vaccinations. According to the US Food and Drug
Administration, safety assessments for vaccines have
often not included appropriate toxicity studies because
vaccines have not been viewed as inherently toxic.
Taken together, these
observations raise plausible concerns about the overall
safety of current childhood vaccination programs…infants
and children should not be viewed as ‘‘small adults’’
with regard to toxicological risk as their unique
physiology makes them much more vulnerable to toxic
insults; (ii) in adult humans Al vaccine adjuvants have
been linked to a variety of serious autoimmune and
inflammatory conditions (i.e., ‘‘ASIA’’), yet children
are regularly exposed to much higher amounts of Al from
vaccines than adults; (iii) it is often assumed that
peripheral immune responses do not affect brain
function. However, it is now clearly established that
there is a bidirectional neuro-immune cross-talk that
plays crucial roles in immunoregulation as well as brain
function. In turn, perturbations of the neuro-immune
axis have been demonstrated in many autoimmune diseases
encompassed in ‘‘ASIA’’ and are thought to be driven by
a hyperactive immune response; and (iv) the same
components of the neuroimmune axis that play key roles
in brain development and immune function are heavily
targeted by Al adjuvants.”
http://vaccinesafetycouncilminnesota.org/wp-content/uploads/2012/01/Mechanisms-of-aluminum-adjuvant-toxicity-and-autoimmunity-in-pediatric-populations.pdf
Just one example of the
great safety measure taken by vaccine researchers (4 day
follow up period!! thats it?):
“Pain at the injection site
(dTpa-IPV: 63.6%; DTPa-IPV: 63.2%) and fatigue
(dTpa-IPV: 26.5%; DTPa-IPV: 23.7%) were the most
commonly reported solicited local and general symptoms,*
during the 4-d follow-up period.* No SAEs or fatalities
were reported.”
http://www.landesbioscience.com/journals/vaccines/article/18650/?show_full_text=true&
“One of the challenges of
evidence-based evaluation of vaccines is that some
effects, e.g. rare adverse effects following
immunization (AEFI) or population effects, are usually
difficult or impossible to assess in pre-marketing
clinical trials due to their limited size and are
unknown at the time of recommendation [6] and [7]. The
respective evidence arises usually through
post-marketing surveillance. Another challenge is the
use of immunogenicity markers in vaccine studies. While
these accepted correlates of protection are adequate for
regulatory purposes, they are considered indirect
evidence and are therefore of lesser quality with regard
to the primary question of how effectively a vaccine can
prevent the disease. Generating the evidence through
randomized controlled trials (RCTs) in the
post-marketing phase might be difficult for ethical
reasons or logistically challenging and very expensive.
Therefore, one often has to rely on epidemiological
observational studies to adjust programs. According to
the principles of epidemiology and the criteria of
evidence-based medicine (EBM), however, observational
studies have greater potential for bias and confounding
compared to RCTs, and may be attributed a lower score of
quality of evidence even though they could have been
designed and implemented very well and lead to results
that are relevant and more valid (e.g. post-licensure
studies on measles vaccine safety [8]). Lower grading
from observational studies could potentially lead to a
lower public confidence in recommendations and
immunization programs “
http://www.sciencedirect.com/science/article/pii/S0264410X1101927X
“Formaldehyde has been
classified as a known human carcinogen (cancer-causing
substance) by the International Agency for Research on
Cancer and as a probable human carcinogen by the U.S.
Environmental Protection Agency. Research studies of
workers exposed to formaldehyde have suggested an
association between formaldehyde exposure and several
cancers, including nasopharyngeal cancer and leukemia.”
http://www.cancer.gov/cancertopics/factsheet/Risk/formaldehyde
“ However, since vaccine
preparation involves the use of materials of biological
origin, vaccines are subject to contamination by
micro-organisms. In fact, vaccine contamination has
occurred; a historical example of vaccine contamination,
for example, can be found in the early days of
development of the smallpox vaccine. The introduction of
new techniques of vaccine virus production on cell
cultures has lead to safer vaccines, but has not
completely removed the risk of virus contamination.
There are several examples of vaccine contamination, for
example, contamination of human vaccines against
poliomyelitis by SV40 virus from the use of monkey
primary renal cells. Several veterinary vaccines have
been contaminated by pestiviruses from foetal calf
serum.
These incidents have lead
industry to change certain practices and regulatory
authorities to develop more stringent and detailed
requirements. But the increasing number of target
species for vaccines, the diversity of the origin of
biological materials and the extremely high number of
known and unknown viruses and their constant evolution
represent a challenge to vaccine producers and
regulatory authorities.”
http://www.sciencedirect.com/science/article/pii/S1045105610000734
for a more indepth look see:
http://vaccineresearchlibrary.com/weekly-scream-8/
and this may be the scariest
of them all..DNA contamination..
Virus-based vaccines are
made in living cells (cell substrates). Some
manufacturers are investigating the use of new cell
lines to make vaccines. The continual growth of cell
lines ensures that there is a consistent supply of the
same cells that can yield high quantities of the
vaccine.
In some cases the cell lines
that are used might be tumorigenic, that is, they form
tumors when injected into rodents. Some of these
tumor-forming cell lines may contain cancer-causing
viruses that are not actively reproducing. Such viruses
are hard to detect using standard methods. These latent,
or “quiet,” viruses pose a potential threat, since they
might become active under vaccine manufacturing
conditions. Therefore, to ensure the safety of vaccines,
our laboratory is investigating ways to activate latent
viruses in cell lines and to detect the activated
viruses, as well as other unknown viruses, using new
technologies. [they are investigating it..so that means
everyone getting vaccines now is in danger of the silent
viruses..fun..umm..no.]
http://www.fda.gov/biologicsbloodvaccines/scienceresearch/biologicsresearchareas/ucm127327.htm
some more about
contamination..
Porcine circovirus type 1 (PCV1) is highly prevalent in
swine and was recently reported in some rotavirus
vaccines. Since animal-derived raw materials, such as
cells, trypsin, and serum, can be a major source of
introducing virus contamination in biological products,
we have investigated PCV1 in several cell lines obtained
from ATCC that have broad use in research, diagnostics,
or vaccine development. It is expected that these cell
lines have been exposed to bovine and porcine viruses
during their establishment and passage history due to
the use of serum and trypsin that was not qualified
according to current testing guidances or processed
using new virus-inactivation methods. This study showed
that Vero, MRC-5, and CEFs, which represent cell
substrates used in some U.S. licensed vaccines, and
other cell lines used in investigational vaccines, such
as MDCK, HEK-293, HeLa, and A549, were negative for PCV1
using a nested PCR assay; some were also confirmed
negative by infectivity analysis. However, MDBK cells,
which are used for some animal vaccines, contained PCV1
sequences, although no virus was isolated. Although the
results showed that PCV infection may not have occurred
under previous culture conditions, the recent cases of
vaccine contamination emphasizes the need for continued
efforts to reduce the likelihood of introducing viruses
from animal-derived materials used in product
manufacture.
http://www.ncbi.nlm.nih.gov/pubmed/21835219?dopt=Abstract
The National Cancer
Institute owned patents for the HPV vaccine. Mmm…
http://vaccineresearchlibrary.com/scream-13-nci-owned-hpv-vaccine-patents/
Autism: a novel form of
mercury poisoning
“Thimerosal, a preservative
added to many vaccines, has become a major source of
mercury in children who, within their first two years,
may have received a quantity of mercury that exceeds
safety guidelines. A review of medical literature and US
government data suggests that: (i) many cases of
idiopathic autism are induced by early mercury exposure
from thimerosal; (ii) this type of autism represents an
unrecognized mercurial syndrome; and (iii) genetic and
non-genetic factors establish a predisposition whereby
thimerosal’s adverse effects occur only in some
children.”
http://www.ncbi.nlm.nih.gov/pubmed/11339848
“Aluminum hydroxide
injections lead to motor deficits and motor neuron
degeneration.”
“Possible causes of GWS
include several of the adjuvants in the anthrax vaccine
and others. The most likely culprit appears to be
aluminum hydroxide. In an initial series of experiments,
we examined the potential toxicity of aluminum hydroxide
in male, outbred CD-1 mice injected subcutaneously in
two equivalent-to-human doses. After sacrifice, spinal
cord and motor cortex samples were examined by
immunohistochemistry. Aluminum-treated mice showed
significantly increased apoptosis of motor neurons and
increases in reactive astrocytes and microglial
proliferation within the spinal cord and cortex. Morin
stain detected the presence of aluminum in the cytoplasm
of motor neurons with some neurons also testing positive
for the presence of hyper-phosphorylated tau protein, a
pathological hallmark of various neurological diseases,
including Alzheimer’s disease and frontotemporal
dementia. A second series of experiments was conducted
on mice injected with six doses of aluminum hydroxide.
Behavioural analyses in these mice revealed significant
impairments in a number of motor functions as well as
diminished spatial memory capacity. The demonstrated
neurotoxicity of aluminum hydroxide and its relative
ubiquity as an adjuvant suggest that greater scrutiny by
the scientific community is warranted.”
http://www.ncbi.nlm.nih.gov/pubmed/19740540
“These findings are
consistent with the hypothesis that immunization with
the recombinant hepatitis B vaccine is associated with
an increased risk of MS, and challenge the idea that the
relation between hepatitis B vaccination and risk of MS
is well understood. “
http://www.neurology.org/content/63/5/838.abstract
“Hepatitis B vaccination
does not generally increase the risk of CNS inflammatory
demyelination in childhood. However, the Engerix B
vaccine appears to increase this risk, particularly for
confirmed multiple sclerosis, in the longer term.”
http://www.ncbi.nlm.nih.gov/pubmed/18843097
Influence of pediatric
vaccines on amygdala growth and opioid ligand binding in
rhesus macaque infants: A pilot study
“In this pilot study, infant
macaques receiving the recommended pediatric vaccine
regimen from the 1990’s displayed a different pattern of
maturational changes in amygdala volume and differences
in amygdala-binding of [11C]DPN following the
MMR/DTaP/Hib vaccinations between T1 and T2 compared
with non-exposed animals. There was also evidence of
greater total brain volume in the exposed group prior to
these vaccinations suggesting a possible effect of
previous vaccinations to which these animals had been
exposed. Because primate testing is an important aspect
of pre-clinical vaccine safety assessment prior to
approval for human use (Kennedy et al. 1997), the
results of this pilot study warrant additional research
into the potential impact of an interaction between the
MMR and thimerosal-containing vaccines on brain
structure and function.”
http://www.ane.pl/pdf/7020.pdf
“A majority of the
ophthalmological complications seen following hepatitis
B vaccination consist of vision loss, optic neuritis,
papillary edema, uveitis, acute placoid pigment
epitheliopathy and central vein occlusion. We present a
9-year-old girl who was referred to our hospital with
decrease in vision and pain in the left eye a week after
hepatitis B vaccination. A diagnosis of vaccine induced
optic neuritis was made.”
https://www.ncbi.nlm.nih.gov/pubmed/19948437
Optic neuritis following hepatitisB vaccination in a_9
year old girl
http://www.ncbi.nlm.nih.gov/pubmed/19948437
Acute Fulminant Myocarditis
after Diphtheria, Polio, and Tetanus Vaccination
A previously healthy
8-month-old female baby, body height 67cm and body
weight 8.0kg, suffered from fever (38.3°C) 12 hours
after she received triple vaccination against
diphtheria, polio, and tetanus. Dyspnea occurred 3 days
later. She presented with poor activity, persistent
dyspnea with subcostal retraction and skin mottling 5
days later. There was no prior history of adverse
reactions to previous diphtheria, polio, and tetanus
vaccinations, or other vaccinations.
poor ventricular
contractility recurred 2 months Cardiac catheterization
showed patent coronary arteries and a left ventricular
ejection fraction of 14%. Endomyocardial biopsy was
still not attempted due to poor general condition. The
patient died while waiting for heart transplantation.
http://www.ncbi.nlm.nih.gov/pubmed/17130313
full text:
http://asianannals.ctsnetjournals.org/cgi/reprint/14/6/e111.pdf
Myocarditis after triple
immunisation.
“We describe a 3 month old
infant who developed myocarditis several hours after
diphtheria, tetanus, and pertussis vaccination. The time
of occurrence of symptoms, the clinical course, and the
negative virological studies suggest a possible
cardiogenic adverse reaction to the vaccine.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1777748/
A case series of children
with apparent mercury toxic encephalopathies manifesting
with clinical symptoms of regressive autistic disorders.
Impairments in social
relatedness and communication, repetitive behaviors, and
stereotypic abnormal movement patterns characterize
autism spectrum disorders (ASDs). It is clear that while
genetic factors are important to the pathogenesis of
ASDs, mercury exposure can induce immune, sensory,
neurological, motor, and behavioral dysfunctions similar
to traits defining or associated with ASDs. The
Institutional Review Board of the Institute for Chronic
Illnesses (Office for Human Research Protections, U.S.
Department of Health and Human Services, IRB number
IRB00005375) approved the present study. A case series
of nine patients who presented to the Genetic Centers of
America for a genetic/developmental evaluation are
discussed. Eight of nine patients (one patient was found
to have an ASD due to Rett’s syndrome) (a) had
regressive ASDs; (b) had elevated levels of androgens;
(c) excreted significant amounts of mercury post
chelation challenge; (d) had biochemical evidence of
decreased function in their glutathione pathways; (e)
had no known significant mercury exposure except from
Thimerosal-containing vaccines/Rho(D)-immune globulin
preparations; and (f) had alternate causes for their
regressive ASDs ruled out. There was a significant
dose-response relationship between the severity of the
regressive ASDs observed and the total mercury dose
children received from Thimerosal-containing
vaccines/Rho (D)-immune globulin preparations. Based
upon differential diagnoses, 8 of 9 patients examined
were exposed to significant mercury from
Thimerosal-containing biologic/vaccine preparations
during their fetal/infant developmental periods, and
subsequently, between 12 and 24 mo of age, these
previously normally developing children suffered mercury
toxic encephalopathies that manifested with clinical
symptoms consistent with regressive ASDs. Evidence for
mercury intoxication should be considered in the
differential diagnosis as contributing to some
regressive ASDs.
http://www.ncbi.nlm.nih.gov/pubmed/17454560
” Inflammation, platelet
reactivity and cardiac autonomic dysfunction increase
the risk of cardiovascular events, but the relationships
between these prognostic markers are poorly defined. In
this study, we investigated the effect of an
inflammatory stimulus (influenza A vaccine) on platelet
activation and cardiac autonomic function.. Together
with an inflammatory reaction, influenza A vaccine
induced platelet activation and sympathovagal imbalance
towards adrenergic predominance. Significant
correlations were found between CRP levels and HRV
parameters, suggesting a pathophysiological link between
inflammation and cardiac autonomic regulation. The
vaccine-related platelet activation and cardiac
autonomic dysfunction may transiently increase the risk
of cardiovascular events.”
http://www.ncbi.nlm.nih.gov/pubmed/20964738
“Narcolepsy is a chronic
disorder presenting with excessive daytime sleepiness,
often accompanied by a transient loss of muscle tone
triggered by strong emotion (cataplexy). Diagnosis is
based on clinical criteria and can be confirmed by
polysomnography followed by a multiple sleep latency
test.1 Estimates of prevalence generally range between
25 and 50 per 100 000, though might be less in some
populations, possibly because of differences in genetic
susceptibility or exposure to aetiological risk
factors.2 Information on incidence is more limited.
Onset can occur at any age2 but is commonest in those
aged 10-19, in whom an incidence of 3.84 per 100 000
person years has been reported.3 The interval between
onset and diagnosis can be long, with a median of 10.5
years in one study.4 Diagnostic delay is less in those
with cataplexy and in younger patients.5 There is a
strong association with human leucocyte antigen (HLA)
DQB1*0602 and reported associations with environmental
factors such as streptococcal infection,6 seasonal
influenza,7 and more recently pandemic A/H1N1 2009
influenza.8
In August 2010 concerns were
raised in Finland and Sweden about a possible
association between narcolepsy and Pandemrix.13 A
subsequent cohort study in Finland reported a 13-fold
increased risk of narcolepsy after vaccination in
children and young people aged 4-19, most of whom had
onset within three months after vaccination and almost
all within six months.14 To evaluate the risk of
narcolepsy after vaccination in England we identified
cases in those aged under 19 with onset since 1 January
2008 and compared the proportion vaccinated with that in
the age matched English population after adjusting for
clinical conditions that were indications for pandemic
vaccination.
The increased risk of
narcolepsy after vaccination with ASO3 adjuvanted
pandemic A/H1N1 2009 vaccine indicates a causal
association, consistent with findings from Finland.”
http://www.bmj.com/content/346/bmj.f794
Detection of Measles Virus
Genomic RNA in Cerebrospinal Fluid of Children with
Regressive Autism: a Report of Three Cases.
In light of encephalopathy
presenting as autistic regression (autistic
encephalopathy, AE) closely following measles-mumps-
rubella (MMR) vaccination, three children underwent
cerebrospinal fluid(CSF) assessments including studies
for measles virus(MV). All three children had
concomitant onset of gastrointestinal (GI) symptoms and
had already had MV genomic RNA detected in biopsies
ofileal lymphoid nodular hyperplasia(LNH). Presence of
MV Fusion(F) gene was examined by TaqMan real- time
quantitative polymerase chain reaction (RT-PCR) in cases
and control CSF samples. The latter were obtained from
three non- autistic MMR-vaccinated children with
indwelling shunts for hydrocephalus. None of the cases
or controls had a history of measles exposure other than
MMR vaccination. Serum and CSF samples were also
evaluated for antibodies to MV and myelin basic
protein(MBP). MV F gene was present in CSF from all
three cases, but not in controls. Genome copy number
ranged from 3.7×10 to 2.42×10 per ng of RNA total. Serum
anti-MBP autoantibodies were detected in all children
with AE. Anti-MBP and MV antibodies were detected in the
CSF of two cases, while the third child had neither
anti-MBP nor MV antibodies detected in his CSF. Findings
are consistent with both an MV (measles virus) etiology
for the AE (autistic encephalopathy) and active viral
replication in these children. They further indicate the
possibility of a virally driven cerebral immunopathology
in some cases of regressive autism.
www.jpands.org/vol9no2/bradstreet.pdf
Among 11, 531 children who
received at least 4 doses of DPT, the risk of asthma was
reduced to (1/2) in children whose first dose of DPT was
delayed by more than 2 months. The likelihood of asthma
in children with delays in all 3 doses was 0.39 (95% CI,
0.18-0.86).
CONCLUSION: We found a
negative association between delay in administration of
the first dose of whole-cell DPT immunization in
childhood and the development of asthma; the association
was greater with delays in all of the first 3 doses. The
mechanism for this phenomenon requires further research.
http://www.ncbi.nlm.nih.gov/pubmed/18207561
“Macrophagic myofasciitis
and chronic fatigue syndrome are severely disabling
conditions which may be caused by adverse reactions to
aluminium-containing adjuvants in vaccines. While a
little is known of disease aetiology both conditions are
characterised by an aberrant immune response, have a
number of prominent symptoms in common and are
coincident in many individuals. Herein, we have
described a case of vaccine-associated chronic fatigue
syndrome and macrophagic myofasciitis in an individual
demonstrating aluminium overload. This is the first
report linking the latter with either of these two
conditions and the possibility is considered that the
coincident aluminium overload contributed significantly
to the severity of these conditions in this individual.
This case has highlighted potential dangers associated
with aluminium-containing adjuvants and we have
elucidated a possible mechanism whereby vaccination
involving aluminium-containing adjuvants could trigger
the cascade of immunological events which are associated
with autoimmune conditions including chronic fatigue
syndrome and macrophagic myofasciitis.
http://www.ncbi.nlm.nih.gov/pubmed/19004564
full text here:
http://www.theoneclickgroup.co.uk/documents/vaccines/Vaccine%20Aluminium%20In%20CFS.pdf
“Our case highlights the
fact that pediatricians should be aware of the
often-dramatic presentation of postvaccination
myopericarditis and its usually benign clinical course.
The diagnosis of myocarditis should be entertained when
acute-onset chest pain is accompanied by ECG changes and
elevated cardiac enzyme levels. In cases in which the
above-described presentation is temporally related to
routine immunizations, the immunizations should be
considered as a possible underlying etiology. “
http://pediatrics.aappublications.org/content/119/6/e1400.full
Conclusion: Susceptibility
to ASD has moderate genetic heritability and a
substantial shared twin environmental component.
http://www.ncbi.nlm.nih.gov/pubmed/21727249
full text here:
http://cirge.stanford.edu/Hallmayer%202011.pdf
. ASDs disproportionately
affect male children. Mercury (Hg) a heavy metal, is
widespread and persistent in the environment. Mercury is
a ubiquitous source of danger in fish, drugs,
fungicides/herbicides, dental fillings, thermometers,
and many other products. Elevated Hg concentrations may
remain in the brain from several years to decades
following exposure. This is important because
investigators have long recognized that Hg is a
neurodevelopmental poison; it can cause problems in
neuronal cell migration and division, and can ultimately
cause cell degeneration and death. Case-reports of
patients have described developmental regressions with
ASD symptoms following fetal and/or early childhood Hg
exposure (flu shots for pregnant women are good says the
CDC?), and epidemiological studies have linked exposure
to Hg with an elevated risk of a patient being diagnosed
with an ASD. Immune, sensory, neurological, motor, and
behavioral dysfunctions similar to traits defining or
associated with ASDs were reported following Hg
(mercury) intoxication with similarities extending to
neuroanatomy, neurotransmitters, and biochemistry. The
sexual dimorphism of ASDs may result from synergistic
neurotoxicity caused by the interaction of testosterone
and Hg; in contrast, estrogen is protective, mitigating
the toxicity of Hg.
http://www.ncbi.nlm.nih.gov/pubmed/16264412
“Starting in 2000, HZ
(herpes zoster – or shingles) surveillance was added to
the project. By 2002, notable increases in HZ incidence
rates were reported among both children and adults with
a prior history of natural varicella. However, CDC
authorities still claimed that no increase in HZ had
occurred in any US surveillance site. The basic
assumptions inherent to the varicella cost-benefit
analysis ignored the significance of exogenous boosting
caused by those shedding wild-type VZV. Also ignored was
the morbidity associated with even rare serious events
following varicella vaccination as well as the morbidity
from increasing cases of HZ among adults. Vaccine
efficacy declined below 80% in 2001. By 2006, because
20% of vaccinees were experiencing breakthrough
varicella and vaccine-induced protection was waning, the
CDC recommended a booster dose for children and, in
2007, a shingles vaccination was approved for adults
aged 60 years and older. In the prelicensure era, 95% of
adults experienced natural chickenpox (usually as
children)-these cases were usually benign and resulted
in long-term immunity. Varicella vaccination is less
effective than the natural immunity that existed in
prevaccine communities. Universal varicella vaccination
has not proven to be cost-effective as increased HZ
morbidity has disproportionately offset cost savings
associated with reductions in varicella disease.
Universal varicella vaccination has failed to provide
long-term protection from VZV disease.”
**personal note : many say
that the rise in shingles that we are experiencing is
because children are not catching chickenpox anymore.
For adults who had the chickenpox as children, coming
into contact with a child that has the chickenpox acts
as an immunity boost against shingles (kinda like the
immune system saying, “hey I remember that..let me send
out some reinforcements..”) but since adults aren’t
getting that boost anymore..shingles is on the rise.
Shingles is more dangerous than chickenpox. We have
traded a mild childhood disease, that was described as a
mild disease that runs its course and is completed
between 5 to 10 days and, “never, of itself, proves
fatal.” (see here for reference:
http://archive.org/stream/variolavacciniah00newe#page/20/mode/2up
for a disease that is much more serious and claims
more lives. But hey..now you can just buy a shingles
vaccine! The reason above is why in the UK, there is no
recommendation for the chickenpox vaccine.
Or as Dr Phillip Welsby, an
infectious diseases expert, explains it,
“Every time adults come into
contact with children who’ve just caught chicken pox,
they get the natural equivalent of a booster shot of the
virus which strengthens their resistance. In the past,
when a child got chicken pox their mother would invite
neighbours’ children to a ‘chicken pox party’ so they,
too, could become infected and get it over with. ‘What
the parents usually didn’t realize was they were
benefiting as well. GPs, for instance, are less likely
to develop shingles, because they are regularly exposed
to children with chicken pox.”
http://www.dailymail.co.uk/health/article-1158655/Why-giving-children-chicken-pox-jab-YOU-shingles.html
Another great article to
read is, “chickenpox: why do children die?”
http://articles.mercola.com/sites/articles/archive/2001/03/17/chicken-pox.aspx
source for main article:
http://www.ncbi.nlm.nih.gov/pubmed/22659447
“Clustering of cases of
insulin dependent diabetes (IDDM) occurring three years
after hemophilus influenza B (HiB) immunization support
causal relationship between immunization and IDDM
(insulin depedent diabetes).”
http://www.ncbi.nlm.nih.gov/pubmed/12911277
“We initiated and funded a
collaborative study with Tuomilehto on the effect of the
Haemophilus influenzae type b vaccine on type 1 diabetes
and found that the data support a causal relation (paper
submitted for publication). Furthermore, the potential
risk of the vaccine exceeds the potential benefit. We
compared a group that received four doses of the
vaccine, a group that received one dose, and a group
that was not vaccinated. The cumulative incidence of
diabetes per 100000 in the three groups receiving four,
one, and no doses of the vaccine was 261, 237, and 207
at age 7 and 398, 376, and 340 at age 10 respectively.
Karvonen et al’s analysis is
not rational, and their conclusion is not supported by
our data.1 Their calculations of relative risk are also
misleadingly low, and we urge readers to check them.
Most researchers would compare the group who received
four doses with the group that was not vaccinated or the
two vaccinated groups with the group that was not
vaccinated. The results of both comparisons reach
significance. The cumulative difference in cases of type
1 diabetes per 100000 between those receiving four doses
and those who were not vaccinated is 54 cases (P=0.013)
at 7 years and 58 cases at 10 years (P=0.029; single
tail Fisher test). The relative risk is 1.26 at 7 years.
The cumulative difference between those receiving four
doses or one dose of the vaccine and those who were not
vaccinated is 42 cases (P=0.016) at 7 years and 47 cases
at 10 years (P=0.028).
The rise in diabetes, just
one potential adverse effect, exceeds the benefit of the
vaccine, which has been estimated to prevent seven
deaths and 7-26 cases of severe disability per 100000
children immunised.2 Even the difference in cases of
diabetes between the groups receiving four doses and one
dose exceeds the mean expected benefit. Temporal changes
in the incidence of diabetes do not explain the
differences since there were an extra 31 cases of type 1
diabetes per 100000 children aged 5-10, and the
incidence of diabetes in this group had been stable for
about 10 years before this.3 Furthermore, sharp rises in
diabetes have been recorded in the United States4 and
the United Kingdom5 after the introduction of the
haemophilus vaccine.”
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1116914/
Published research shows
that personal benefit from vaccinating healthy
nonelderly adults is small and there is no evidence that
it is any different for HCWs. The studies aiming to
prove the widespread belief that healthcare worker
vaccination decreases patient morbidity and mortality
are heavily flawed and the recommendations for
vaccination biased. No reliable published evidence shows
that healthcare workers’ vaccination has substantial
benefit for their patients—not in reducing patient
morbidity or mortality and not even in increasing
patient vaccination rates. Conclusion. The arguments for
uniform healthcare worker influenza vaccination are not
supported by existing literature. The decision whether
to get vaccinated should, except possibly in extreme
situations, be that of the individual healthcare worker,
without legal, institutional, or peer coercion.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502850/
The association between
sudden infant death syndrome and immunization is
frequently discussed. Serious adverse events following
vaccination have generally been defined as those adverse
events that result in permanent disability,
hospitalization or prolongation of hospitalization, life
threatening illness, congenital anomaly or death. They
are generally referred to the inherent properties of the
vaccine (vaccine reaction) or some error in the
immunization process (programme error). The event could
also be totally unrelated but only temporally linked to
immunization (coincidental event). A fatal case of a
3-month-old female infant, who died within 24 h of
vaccination with hexavalent vaccine is presented.
Clinical data, post-mortem findings (acute pulmonary
oedema, acute pulmonary emphysema), quali-quantitative
data collected from immunohistochemical staining
(degranulating mast cells) and laboratory analysis with
a high level of beta-tryptase in serum, 43.3 microg/l,
allows us to conclude that acute respiratory failure
likely due to post hexavalent immunization-related shock
was the cause of death.
http://www.ncbi.nlm.nih.gov/pubmed/18538957
Despite wide use of the
influenza vaccine, relatively little is known about its
effect on the measurement of inflammatory markers.
Because inflammatory markers such as C-reactive protein
(CRP) are increasingly being used in conjunction with
lipids for the clinical assessment of cardiovascular
disease and in epidemiologic studies, we evaluated the
effect of influenza vaccination on markers of
inflammation and plasma lipid concentrations. We drew
blood from 22 healthy individuals 1 to 6 hours before
they were given an influenza vaccination and 1, 3, and 7
days after the vaccination. Plasma CRP, interleukin
(IL)-6, monocyte chemotactic protein 1, tumor necrosis
factor alpha, IL-2 soluble receptor alpha, and serum
amyloid A were measured, and differences in mean
concentrations of absolute and normalized values on days
1, 3, and 7 were compared with mean baseline values.
There was a significant increase in mean IL-6 (P < .01
absolute values, P < .001 normalized values) on day 1
after receiving the influenza vaccine. The mean
increases in normalized high sensitivity CRP values were
significant on day 1 (P < .01) and day 3 (P = .05),
whereas the mean increase in normalized serum amyloid A
was significant only on day 1 (P < .05). No significant
changes were seen in mean concentrations of IL-2 soluble
receptor alpha, monocyte chemotactic protein-1, or tumor
necrosis factor-alpha. Of the lipids, significant
decreases in mean concentrations of normalized
triglyceride values were seen on days 1 (P < .05), 3 (P
< .001), and 7 (P < .05) after vaccination. Our findings
show that the influenza vaccination causes transient
changes in select markers of inflammation and lipids.
Consequently, clinical and epidemiologic interpretation
of the biomarkers affected should take into account the
possible effects of influenza vaccination.
http://www.ncbi.nlm.nih.gov/pubmed/15976761
“A continuous breeding
reproduction study design was utilized to examine the
reproductive toxicity of ethylene glycol monobutyl ether
(EGBE) and ethylene glycol monophenyl ether (EGPE)(EGPE
= vaccine ingredient). continuous breeding reproduction
study design was utilized to examine the reproductive
toxicity of ethylene glycol monobutyl ether (EGBE) and
ethylene glycol monophenyl ether (EGPE).. Both male and
female mice were dosed for 7 days prior to and during a
98-day cohabitation period. EGBE was toxic at the high
(2%) and mid dose (1%) to adult F0 female mice: 13 out
of 22 females at the high dose and 6 out of 20 at the
mid dose died during the cohabitation period. Both the
high- and mid-dose animals produced fewer litters/pair,
fewer pups/litter, with decreased pup weight. These
effects occurred in the presence of decreased body
weight, decreased water consumption, and increased
kidney weight. A crossover mating trial indicated that
the reproductive effects could be attributed primarily
to an effect on the female. This was substantiated at
necropsy where testes and epididymis weights were normal
as were sperm number and motility. Fertility of the
offspring of the 0.5% group was normal in the presence
of increased liver weights. With respect to EGPE, there
was no change in the ability to produce five litters
during the continuous breeding period. There was,
however, a significant but small (10-15%) decrease in
the number of pups/litter and in pup weight in the
high-dose group. A crossover mating trial suggested a
female component of the reproductive toxicity of EGPE.
While fertility was only minimally compromised, severe
neonatal toxicity was observed. By Day 21 there were
only 8 out of 40 litters in the mid- and high-dose
groups which had at least one male and female/litter.
Second generation reproductive performance of the
mid-dose group (1.25%) was unaffected except for a small
decrease in live pup weight. In summary the reproductive
toxicity of EGBE and EGPE was only evident in the female
and occurred at doses which elicited general toxicity.
EGBE was particularly toxic to adult female mice while
EGPE was particularly toxic to immature mice of both
sexes.” (10)
** I had to read this about
ten times just to make sure that I was reading it right.
Did that really just say what I thought it did? Does
anyone else notice how the authors try their hardest to
play down the results in the group that received EGPE?
But if you read it a few times..you will quickly realize
that the results for the group that received
2-phenoxyethanol are not good.
•there was a slow decline in
fertility that caused a drop in the weight and health of
the next generation.
• severe neonatal (infants)
toxicity was observed.
•the abstract never gave the
information needed to know how many in the EGPE group
died..but it seems more died in the EGPE group than in
the EGBE group. Since it never gave the orginal number
of pups/liter there is no way to know.
• the other ether in the
study caused deaths and toxic events to happen to the
adult female mice. The glysol ether that is in several
pediatric vaccines, 2-phenoxyethanol, was particularly
toxic and caused death in the baby and children mice of
both sexes.
•and these results were what
happened after the mice ate 2-phenoxyethanol..infants
and children are injected with this substance. (17 times
before the age of 18, as i mentioned above)
http://www.ncbi.nlm.nih.gov/pubmed/2086313
“In summary, ethylene glycol
monophenyl ether produced significant reproductive and
developmental toxicity..Ethylene glycol monophenyl ether
caused significant toxicity in growing animals, as
evidenced by the reduced body weight in neonates in
Tasks 2, 3, and 4, and the large increase in postnatal
lethality as the animals grew to the age of mating.”
(11)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1470243/pdf/envhper00326-0221.pdf
“Neonatal female rats were
injected ip (0.1 ml/rat) with Tween 80 in 1, 5 or 10%
aqueous solution on days 4-7 after birth. Treatment with
Tween 80 accelerated maturation, prolonged the oestrus
cycle, and induced persistent vaginal oestrus. The
relative weight of the uterus and ovaries was decreased
relative to the untreated controls. Squamous cell
metaplasia of the epithelial lining of the uterus and
cytological changes in the uterus were indicative of
chronic oestrogenic stimulation. Ovaries were without
corpora lutea, and had degenerative follicles”
http://www.ncbi.nlm.nih.gov/pubmed/8473002?dopt=Abstract
“Acquired autoimmunity
syndromes occur after viral vaccinations. Molecular
mimicry is involved in these phenomena as is the
necessity for the presence of two chemically
complimentary antigens and an immunologic adjuvant. The
HLA pattern of the host is also an important factor. The
example used to explain these phenomena is demyelinating
disease that follows hepatitis B vaccination. The
somatic antigen of the hepatitis B virus in the vaccine
has chemical complimentarity with the Epstein-Barr virus
antigen in the vaccine recipient. The Epstein-Barr virus
shows molecular mimicry with human myelin. The
immunologic adjuvant is either present in the vaccine or
muramyl peptides in the individual who is vaccinated.
Why more than one type of autoimmune disease occurs is
explained by the fact that specific autoimmune T-cells
have been shown to develop clones that attack multiple
human tissues.”
http://www.ncbi.nlm.nih.gov/pubmed/17630224
“Universal hepatitis B
vaccination was recommended for U.S. newborns in 1991;
however, safety findings are mixed. The association
between hepatitis B vaccination of male neonates and
parental report of autism diagnosis was determined.
Logistic regression was used to estimate the odds for
autism diagnosis associated with neonatal hepatitis B
vaccination among boys age 3-17 years, born before 1999,
adjusted for race, maternal education, and two-parent
household. Boys vaccinated as neonates had threefold
greater odds for autism diagnosis compared to boys never
vaccinated or vaccinated after the first month of life.
Non-Hispanic white boys were 64% less likely to have
autism diagnosis relative to nonwhite boys. Findings
suggest that U.S. male neonates vaccinated with the
hepatitis B vaccine prior to 1999 (from vaccination
record) had a threefold higher risk for parental report
of autism diagnosis compared to boys not vaccinated as
neonates during that same time period. Nonwhite boys
bore a greater risk.”
http://www.ncbi.nlm.nih.gov/pubmed/21058170
“Vaccine-type rotavirus was
detected in all 50 antigen-positive specimens and 8 of 8
antigen-negative specimens. Nine (75%) of 12
EIA-positive and 1 EIA-negative samples tested
culture-positive for vaccine-type rotavirus. Fecal
shedding of rotavirus vaccine virus after the first dose
of RV5 occurred over a wide range of post-vaccination
days not previously studied.”
http://www.ncbi.nlm.nih.gov/pubmed/21477676
“The FluMist influenza
vaccine strains replicate in the nasopharynx and can be
recovered and cultured from respiratory secretions of
vaccinated individuals (shed). The pattern and duration
of shedding is important to understand because with
prolonged shedding at high titer there is a theoretical
risk of loss of attenuated phenotype, reassortment with
wild-type influenza virus during influenza season, and
transmission of vaccine virus to unvaccinated people,
some of whom may be immuno-compromised and/or at risk
for complications of live viral infections. “
“additional shedding samples collected every 7 days …
though some individuals shed vaccine strain virus as
late as day 28”
www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM259175.pdf
“The RotaTeq vaccine
contains five live, attenuated strains derived through
laboratory reassortment of human rotavirus strains with
a bovine rotavirus strain. Three RotaTeq strains each
contain a single human rotavirus gene segment and ten
bovine rotavirus segments, and two strains contain two
human strain segments and nine bovine strain segments.
In the study, RotaTeq was detected in 16 stool samples.
Ten of these contained between one and four individual
vaccine component strains. Six samples were found to
contain a vaccine-derived G1P[8] (vdG1P[8]) strain.
vdG1P[8] is believed to be the product of a genetic
reassortment event in which the G1 gene segment of
strain WI79-9 is inserted into strain WI79-4, as
evidenced by the association of G1-VP7 and P[8]-VP4
human rotavirus genes with the M2-VP3 and I2-VP6 of the
bovine rotavirus. Donato et al. observed that
approximately a fifth of the infants having diarrhea
within 2 weeks of rotavirus vaccination were shedding
vaccine strain components exclusive of any detectable
enteric pathogen.”
http://www.ncbi.nlm.nih.gov/pubmed/23249230
FULL TEXT
http://www.expert-reviews.com/doi/full/10.1586/erv.12.114
“Analysis of 36 individuals
over age 60 years who were immunized with Zostavax
revealed varicella zoster virus DNA in swabs of skin
inoculation sites obtained immediately after
immunization in 18 (50%) of 36 subjects and in saliva
collected over 28 days in 21 (58%) of 36 subjects.
Genotypic analysis of DNA extracted from 9 random saliva
samples identified vaccine virus in ALL instances. In
some immunized individuals over age 60, vaccine virus
DNA is shed in saliva up to 4 weeks.”
Zostavax contains live
attenuated VZV, and the package insert warns newly
vaccinated individuals to avoid contact for an
unspecified time with newborn infants, immunosuppressed
individuals, and pregnant women who have not had chicken
pox or have not been immunized for chicken pox. Because
VZV DNA is present in saliva of zoster patients for at
least 2 weeks [5] and VZV in saliva can also be
infectious [6], we examined the inoculation site and
saliva of Zostavax-vaccinated subjects for the presence
of VZV DNA for 4 weeks after immunization”
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096786/
“The US childhood
immunization schedule requires 26 vaccine doses for
infants aged less than 1 year, THE MOST IN THE WORLD,
yet 33 nations have better Infant Mortality Rates (IMR).
Using linear regression, the immunization schedules of
these 34 nations were examined and a correlation
coefficient of 0.70 (p < 0.0001) was found between IMRs
and the number of vaccine doses routinely given to
infants. When nations were grouped into five different
vaccine dose ranges (12–14, 15–17, 18–20, 21–23, and
24–26), 98.3% of the total variance in IMR was explained
by the unweighted linear regression model. These
findings demonstrate a counter-intuitive relationship:
nations that require more vaccine doses tend to have
higher infant mortality rates. Efforts to reduce the
relatively high UNITED STATES INFANT MORTALITY RATE have
been elusive. Finding ways to lower preterm birth rates
should be a high priority. However, preventing premature
births is just a partial solution to reduce infant
deaths. A closer inspection of correlations between
vaccine doses, biochemical or synergistic toxicity, and
IMRs, is essential. All nations—rich and poor, advanced
and developing—have an obligation to determine whether
their immunization schedules are achieving their desired
goals.”
http://het.sagepub.com/content/early/2011/05/04/0960327111407644.full.pdf+
“Repeated immunization with
antigen causes systemic autoimmunity in mice otherwise
not prone to spontaneous autoimmune diseases.
Overstimulation of CD4+ T cells led to the development
of autoantibody-inducing CD4+ T (aiCD4+ T) cell which
had undergone T cell receptor (TCR) revision and was
capable of inducing autoantibodies.” “Systemic
autoimmunity appears to be the inevitable consequence of
over-stimulating the host’s immune ‘system’ by repeated
immunization with antigen, to the levels that surpass
system’s self-organized criticality.”
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795160/
“Vaccine-type rotavirus was
detected in all 50 antigen-positive specimens and 8 of 8
antigen-negative specimens. Nine (75%) of 12
EIA-positive and 1 EIA-negative samples tested
culture-positive for vaccine-type rotavirus. Fecal
shedding of rotavirus vaccine virus after the first dose
of RV5 occurred over a wide range of post-vaccination
days not previously studied.”
http://www.ncbi.nlm.nih.gov/pubmed/21477676
“ Effectiveness of trivalent
inactivated influenza vaccine in influenza-related
hospitalization in children: a case-control study.”
“Using the
Cochran-Mantel-Haenszel test for asthma status
stratification, there was a significant association
between hospitalization in asthmatic subjects and TIV (p
= 0.001). TIV did not provide any protection against
hospitalization in pediatric subjects, especially
children with asthma. On the contrary, we found a
threefold increased risk of hospitalization in subjects
who did get the TIV vaccine. This may be a reflection
not only of vaccine effectiveness but also the
population of children who are more likely to get the
vaccine.” Allergy Asthma Proc. 2012 Mar-Apr;33(2):e23-7.
http://www.ncbi.nlm.nih.gov/pubmed/22525386
“There are significantly
elevated risks of primarily emergency room visits
approximately one to two weeks following 12 and 18 month
vaccination. Future studies should examine whether these
events could be predicted or prevented.”
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236196/
Administration of thimerosal
to infant rats increases overflow of glutamate and
aspartate in the prefrontal cortex: protective role of
dehydroepiandrosterone sulfate.
http://www.ncbi.nlm.nih.gov/pubmed/22015977
“Our data suggests that the
current schedule of acellular pertussis vaccine doses is
insufficient to prevent outbreaks of pertussis.”
http://cid.oxfordjournals.org/content/early/2012/03/13/cid.cis287.short
“Our unvaccinated and
under-vaccinated population did not appear to contribute
significantly to the increased rate of clinical
pertussis. Surprisingly, the highest incidence of
disease was among previously vaccinated children in the
eight to twelve year age group.”
http://www.ncbi.nlm.nih.gov/pubmed/22423127
“In some cases the cell
lines (aborted babycells) that are used might be
tumorigenic, that is, they form tumors when injected
into rodents. Some of these tumor-forming cell lines may
contain cancer-causing viruses that are not actively
reproducing. Such viruses are hard to detect using
standard methods. These latent, or “quiet,” viruses pose
a potential threat, since they might become active under
vaccine manufacturing conditions.”
Xenotropic murine leukemia
virus-related virus (XMRV) is a recently discovered
human retrovirus that has been found in both chronic
fatigue syndrome & prostate cancer patients. There is a
potential safety concern regarding XMRV in cell
substrates used in vaccines
http://www.fda.gov/biologicsbloodvaccines/scienceresearch/biologicsresearchareas/ucm127327.htm
“Unvaccinated children
tended to be white, to have a mother who was married and
had a college degree, to live in a household with an
annual income exceeding $75,000 dollars, and to have
parents who expressed concerns regarding the safety of
vaccines and indicated that medical doctors have little
influence over vaccination decisions for their children.”
http://www.ncbi.nlm.nih.gov/pubmed/15231927
“Although persons often use
vaccination and immunization interchangeably in
reference to active immunization (VACCINES), the terms
are not synonomous because the administration of an
immunobiologic cannot be automatically equated with the
development of adequate immunity.”
http://www.cdc.gov/mmwr/PDF/rr/rr4301.pdf
“Hib immunization
contributed to an increased risk for H. influenzae type
a meningitis through selection of circulating H.
influenzae type a clones. the incidence for H.
influenzae type a meningitis increased 8-fold”
http://jid.oxfordjournals.org/content/187/1/109.full.pdf+html
“Virus-induced autoimmunity
may play a causal role in autism. To examine the
etiologic link of viruses in this brain disorder, we
conducted a serologic study of measles virus, mumps
virus, and rubella virus. Viral antibodies were measured
by enzyme-linked immunosorbent assay in the serum of
autistic children, normal children, and siblings of
autistic children. The level of measles antibody, but
not mumps or rubella antibodies, was significantly
higher in autistic children as compared with normal
children (P = 0.003) or siblings of autistic children (P
http://www.ncbi.nlm.nih.gov/pubmed/12849883
“Our findings show a
positive correlation between the number of vaccine doses
administered and the percentage of hospitalizations and
deaths. Since vaccines are given to millions of infants
annually, it is imperative that health authorities have
scientific data from synergistic toxicity studies on all
combinations of vaccines that infants might receive. “
http://het.sagepub.com/content/31/10/1012.abstract?maxtoshow&HITS=10&hits=10&RESULTFORMAT&fulltext=vaccine+&andorexactfulltext=and&searchid=1&FIRSTINDEX=10&resourcetype=HWCIT
Maternal transfer of mercury
to the developing embryo/fetus: is there a safe level?
“This study focused on
standardized embryonic and fetal Hg exposures via
primary exposure to the pregnant mother of two common Hg
sources (dietary fish and parenteral vaccines). Data
demonstrated that Hg exposures, particularly during the
first trimester of pregnancy, at well-established dose/weight
ratios produced severe damage to humans including death.
“ Toxicological & Environmental Chemistry Vol 94 2012
http://www.tandfonline.com/doi/full/10.1080/02772248.2012.724574
“reporting bias was too low
to explain the magnitude increase in fetal-demise
reporting rates in the VAERS database relative to the
reported annual trends. Thus, a synergistic fetal
toxicity likely resulted from the administration of both
the pandemic (A-H1N1) and seasonal influenza vaccines
during the 2009/2010 season.”
http://www.ncbi.nlm.nih.gov/pubmed/23023030
“Hepatitis B vaccine might
be followed by various rheumatic conditions and might
trigger the onset of underlying inflammatory or
autoimmune rheumatic diseases. “
http://www.ncbi.nlm.nih.gov/pubmed/10534549
“Autoimmunity to the central
nervous system (CNS), especially to myelin basic protein
(MBP), may play a causal role in autism, a
neurodevelopmental disorder. Because many autistic
children harbor elevated levels of measles antibodies,
we conducted a serological study of
measles-mumps-rubella (MMR) and MBP autoantibodies.
Using serum samples of 125 autistic children and 92
control children, antibodies were assayed by ELISA or
immunoblotting methods. ELISA analysis showed a
significant increase in the level of MMR antibodies in
autistic children. Immunoblotting analysis revealed the
presence of an unusual MMR antibody in 75 of 125 (60%)
autistic sera but not in control sera. This antibody
specifically detected a protein of 73-75 kD of MMR. This
protein band, as analyzed with monoclonal anti bodies,
was immunopositive for measles hemagglutinin (HA)
protein but not for measles nucleoprotein and rubella or
mumps viral proteins. Thus the MMR antibody in autistic
sera detected measles HA protein, which is unique to the
measles subunit of the vaccine. Furthermore, over 90% of
MMR antibody-positive autistic sera were also positive
for MBP autoantibodies, suggesting a strong association
between MMR and CNS autoimmunity in autism. Stemming
from this evidence, we suggest that an inappropriate
antibody response to MMR, specifically the measles
component thereof, might be related to pathogenesis of
autism.”
http://www.ncbi.nlm.nih.gov/pubmed/12145534
Conclusions: Children
vaccinated in infancy are at increased risk of hepatitis
B virus infection in the late teens. The risk of chronic
carriage after sexual exposure needs further assessment
to determine if booster vaccines are necessary.
http://www.bmj.com/content/325/7364/569
Abstract
A traditional infectious disease vaccine is a
preparation of live attenuated, inactivated or killed
pathogen that stimulates immunity. Vaccine immunologic
adjuvants are compounds incorporated into vaccines to
enhance immunogenicity. Adjuvants have recently been
implicated in the new syndrome named ASIA autoimmune/inflammatory
syndrome induced by adjuvants. The objective describes
the frequencies of post-vaccination clinical syndrome
induced by adjuvants. We performed a cross-sectional
study; adverse event following immunization was defined
as any untoward medical occurrence that follows
immunization 54 days prior to the event. Data on
vaccinations and other risk factors were obtained from
daily epidemiologic surveillance. Descriptive statistics
were done using means and standard deviation, and odds
ratio adjusted for potential confounding variables was
calculated with SPSS 17 software. Forty-three out of 120
patients with moderate or severe manifestations
following immunization were hospitalized from 2008 to
2011. All patients fulfilled at least 2 major and 1
minor criteria suggested by Shoenfeld and Agmon-Levin
for ASIA diagnosis. The most frequent clinical findings
were pyrexia 68 %, arthralgias 47 %, cutaneous disorders
33 %, muscle weakness 16 % and myalgias 14 %. Three
patients had diagnosis of Guillain-Barre syndrome, one
patient had Adult-Still’s disease 3 days after
vaccination. A total of 76 % of the events occurred in
the first 3 days post-vaccination. Two patients with
previous autoimmune disease showed severe adverse
reactions with the reactivation of their illness. Minor
local reactions were present in 49 % of patients.
Vaccines containing adjuvants may be associated with an
increased risk of autoimmune/inflammatory adverse events
following immunization
http://www.ncbi.nlm.nih.gov/pubmed/23576057
Autoimmunity following
hepatitis B vaccine as part of the spectrum of
‘Autoimmune (Auto-inflammatory) Syndrome induced by
Adjuvants’ (ASIA): analysis of 93 cases.
OBJECTIVES:
In this study we analyzed the clinical and demographic
manifestations among patients diagnosed with immune/autoimmune-mediated
diseases post-hepatitis B vaccination. We aimed to find
common denominators for all patients, regardless of
different diagnosed diseases, as well as the correlation
to the criteria of Autoimmune (Auto-inflammatory)
Syndrome induced by Adjuvants (ASIA).
PATIENTS AND METHODS:
We have retrospectively analyzed the medical records of
114 patients, from different centers in the USA,
diagnosed with immune-mediated diseases following
immunization with hepatitis-B vaccine (HBVv). All
patients in this cohort sought legal consultation. Of
these, 93/114 patients diagnosed with disease before
applying for legal consultation were included in the
study. All medical records were evaluated for
demographics, medical history, number of vaccine doses,
peri-immunization adverse events and clinical
manifestations of diseases. In addition, available blood
tests, imaging results, treatments and outcomes were
recorded. Signs and symptoms of the different
immune-mediated diseases were grouped according to the
organ or system involved. ASIA criteria were applied to
all patients.
RESULTS:
The mean age of 93 patients was 26.5 ± 15 years; 69.2%
were female and 21% were considered autoimmune
susceptible. The mean latency period from the last dose
of HBVv and onset of symptoms was 43.2 days. Of note,
47% of patients continued with the immunization program
despite experiencing adverse events. Manifestations that
were commonly reported included neuro-psychiatric (70%),
fatigue (42%) mucocutaneous (30%), musculoskeletal (59%)
and gastrointestinal (50%) complaints. Elevated titers
of autoantibodies were documented in 80% of sera tested.
In this cohort 80/93 patients (86%), comprising 57/59
(96%) adults and 23/34 (68%) children, fulfilled the
required criteria for ASIA.
CONCLUSIONS:
Common clinical characteristics were observed among 93
patients diagnosed with immune-mediated conditions
post-HBVv, suggesting a common denominator in these
diseases. In addition, risk factors such as history of
autoimmune diseases and the appearance of adverse event(s)
during immunization may serve to predict the risk of
post-immunization diseases. The ASIA criteria were found
to be very useful among adults with post-vaccination
events. The application of the ASIA criteria to
pediatric populations requires further study.
http://www.ncbi.nlm.nih.gov/pubmed/22235045
Vaccination may be
associated with autoimmune disease (title of article
press link to read)
http://www.feingold.org/Research/PDFstudies/Tishler2004-open.pdf
Antigen-presenting Cell
Activation: a Link Between Infection and Autoimmunity?
The onset of autoimmune
diseases such as type I diabetes and multiple sclerosis
is often thought to be associated with infection. This
has led to studies of molecular mimicry between
infectious agents and the self-antigens associated with
autoimmunity. Despite many claims, however, a single
causative infectious agent for autoimmunity has not been
found. An alternative possibility is that many
infectious agents are capable of non-specifically
enhancing the likelihood of an autoimmune attack. Here
we show how infectious agents may activate
antigen-presenting cells leading to the activation of
autoreactive T cells by otherwise innocuous antigens.
The mechanism of activation involves upregulation of
co-stimulatory molecules on the antigen-presenting cell
resulting in a lowering of the threshold required for
activation. These results help explain how diverse
infectious agents could cause autoimmune disease in
susceptible individuals.
http://www.sciencedirect.com/science/article/pii/S0896841100904980
Pemphigus is an autoimmune
blistering disease caused by autoantibodies against
epithelial intercellular components. Its etiology is
unknown, and neoplasms, antecedent infections or
medications are considered possible triggering factors
for the disease in some cases. We describe the first
case of pemphigus following a hepatitis B virus
vaccination. We suggest that in some cases vaccination
may be the triggering factor for pemphigus in
genetically predisposed individuals and physicians
should be aware of this possible association.
Read More:
http://informahealthcare.com/doi/abs/10.1080/08916930400027078
Discussion
There is increasing evidence that GBS is an autoimmune
disease. Various autoantibodies to gangliosides were
described in GBS patients (4,5), and T cells with
cross-reactivity to nervesheath
components (4). The disease is related in most cases to
respiratory or gastrointestinal infections and vaccines,
resulting in demyelination or axonal degeneration (2).
The target of the immune attack differs with the
clinical subtypes of GBS (3). Rarely is GBS related to
Hodgkin’s lymphoma (6) or autoimmune disease such as
systemic lupus erythematosus (7). Infection with the
following microorganisms can cause GBS: Campylobacter
jejuni, in 25-41% of GBS patients, Epstein-Barr virus,
cytomegalovirus (2), HIV infection, Mycoplasma
pneumoniae, shigella, clostridium (8), and Haemophilus
influenzae (9).
Vaccines reportedly related
to the appearance of GBS include influenza, tetanus
toxoid, BCG, rabies, smallpox, mumps, rubella, oral
poliovirus vaccine, hepatitis B vaccines, either plasma
derived or recombinant vaccine and diphtheria vaccine
(10). The influenza vaccine in 1976 (“swine flue” or New
Jersey 76) caused a 4- to 8-fold increase in the rate of
GBS occurring 6-8
weeks after vaccination (11,12). Subsequent studies of
influenza-vaccinated patients showed no increase in the
GBS rate (13).
In a review of the English
literature another 19 cases of hepatitis B vaccination
were reported to precede the symptoms of GBS (14-22) (Table
I). The plasma-derived hepatitis B vaccine
became commercially available in June 1982. Shaw et al.
(15) documented the first 3 years of postmarketing
surveillance for neurologic adverse events after
vaccination among 850,000 persons,
mostly health workers, who received the HBV vaccine.
Nine cases of GBS were reported up to 7 weeks after
vaccination. One case was reported as atypical and 5
cases were compatible with a viral infection before the
appearance of the neurological symptoms. GBS was
reported as occurring significantly more often then
expected when compared with the Center of Disease
Control GBS background rate (11), but not when compared
with the Olmsted County rate (23). The authors
calculated that, taking into account age, sex and
under-reporting, the rate of GBS was slightly higher in
the vaccinated group, but concluded that no definite
epidemiologic association could be made.
Mcmahon et al. (17)
determined the incidence of adverse reactions from the
plasma-derived hepatitis B vaccine in Alaska. Out of
43,618 subjects who received 101,360 injections, 2
patients
developed GBS 3 and 9 months after the last injection.
Their conclusion was that the vaccine was safe and that
the incidence of GBS was not increased. The authors
claimed that the adverse events caused by the
plasma-derived HBV vaccine are due to the preservative
material thimerosal, a mercurial compound that was found
to be neurotoxic and is not included in the HBV
vaccines since 1999 and to aluminium hydroxide, used as
an adjuvant. Both compounds were also used in the
recombinant vaccine.
In addition to our patient,
8 case reports of GBS after hepatitis B vaccine have
been reported (14,16,18-22), 3 of them after receiving
the yeast derived recombinant DNA hepatitis B vaccine.
One of the patients died after a multiorgan failure,
septic shock and adult respiratory distress syndrome.
Aneuropathologic examination revealed an inflammatory
cell infiltrate in the gray
matter especially in the anterior horn of the spinal
cord, and small foci of macrophages in the long tracts.
Most of the cells appeared around blood vessels, but
were also found in the parenchyma, close to nerve cells
(21).
The pathogenesis of
hepatitis B vaccine associated with GBS is not clear.
The following mechanisms are suggested:
1 ) Molecular mimicry: As in
other autoimmune disorders appearing after vaccination,
molecular mimicry is suspected. Hepatitis B surface
protein may provoke an autoimmune attack on a similar
protein present in the nerve cells. In molecular mimicry
involving T lymphocytes these cells recognize their
antigen as peptide-bound to MHC molecule. The microbial
antigen has the same shape as a self antigenic epitope
bound to the same MHC molecule. The DNA sequence of HBV
was found to be homologous to myelin basic protein (23).
2) Another coincidental
infection: Most of the vaccine recipients are at high
risk for infection with EBV, C M V and HTLV 3, that also
can cause demyelinating disease (18).
3) Immune complex disease:
Five cases of GBS have been reported in patients
suffering from infection with HBV. In the acute phase of
GBS, immune complexes containing hepatitis B surface
antigen were found in the serum and cerebrospinal fluid,
but not in the sural nerve. Those immune complexes were
not present when the hepatitis was first detected, but
only after the appearance of
neurological symptoms, and disappeared when the
inflammatory phase of the disease had ended (24, 25).
Immune complexes without a
known antigen were found in other cases of GBS in
various organs. The immune complexes can transfer
through the blood-nerve barrier and may be deposited in
the endonerium and injure nerve fibers (25). Treatment
with plasmapheresis or IVIG may eliminate those immune
complexes.
Recently, the presence of
glycolipid (ganglioside) specific antibodies has been
found to be associated with neurological disease, in
particular with GBS. The pathogenic potential of these
antibodies has remained unclear. Several mechanisms by
which anti-ganglioside antibodies may exert their
potential pathogenic effect have been proposed. Direct
binding of anti-ganglioside
antibodies to axon or Schwann cells might disturb ion
fluxes and cause partial nerve conduction block (26).
Naturally occurring
antibodies cross reacting with gangliosides may become
pathogenic after affinity maturation and class switching
initiated by preceding infection.
The hepatitis B vaccine has
been used routinely for almost 20 years. Most of the
side effects are local or transient minor reactions. The
rate of the adverseevents is 1 in 15,500 doses. Major
reactions are rare and include variable autoimmune
phenomena: erythema nodosum, lichen planus, acute
urticaria, polyarthritis, including rheumatoid arthritis
and reactive arthritis, vasculitis, glomerulonephritis,
Evan’s syndrome and thrombocytopenic purpura.
Neurological complications
include acute cerebellar ataxia and autoimmune
demyelinating disorders including multiple sclerosis,
transverse myelitis and GBS (27). These reactions are
sporadic and there is no clear evidence that the rate of
GBS or multiple sclerosis is more common among the
vaccinated population.
Hepatitis B vaccine is
important and, according to the available data, the
prevention of hepatitis B outweighs the rare incidence
of diseases reported after vaccination. Further animal
studies
and evaluation of the risk factors for these adverse
effects are indicated.
http://www.clinexprheumatol.org/article.asp?a=2492
Guillain-Barre Syndrome
after Vaccination in United States: Data From the
Centers for Disease Control and Prevention/Food and Drug
Administration Vaccine Adverse Event Reporting System
(1990-2005)
Methods: We used data for
1990 to 2005 from the Vaccine Adverse Event Reporting
System, which is a cooperative program of the Centers
for Disease Control and Prevention and the US Food and
Drug Administration.
Results: There were 1000
cases (mean age, 47 years) of GBS reported after
vaccination in the United States between 1990 and 2005.
The onset of GBS was within 6 weeks in 774 cases, >6
weeks in 101, and unknown in 125. Death and disability
after the event occurred in 32 (3.2%) and 167 (16.7%)
subjects, respectively. The highest number (n = 632) of
GBS cases was observed in subjects receiving influenza
vaccine followed by hepatitis B vaccine (n = 94). Other
vaccines or combinations of vaccines were associated
with 274 cases of GBS. The incidence of GBS after
influenza vaccination was marginally higher in subjects
<65 years compared with those ≥65 years (P = 0.09); for
hepatitis vaccine, the incidence was significantly
higher (P < 0.0001) in the <65 group. Death was more
frequent in subjects ≥65 years compared with those <65
years (P < 0.0001). Conclusions: Our results suggest
that vaccines other than influenza vaccine can be
associated with GBS. Vaccination-related GBS results in
death or disability in one fifth of affected individuals,
which is comparable to the reported rates in the general
GBS population
http://journals.lww.com/jcnmd/Abstract/2009/09000/Guillain_Barre_Syndrome_after_Vaccination_in.1.aspx
Autoimmune reactions to
vaccinations may rarely be induced in predisposed
individuals by molecular mimicry or bystander activation
mechanisms. Autoimmune reactions reliably considered
vaccine-associated, include Guillain-Barré syndrome
after 1976 swine influenza vaccine, immune
thrombocytopenic purpura after measles/mumps/rubella
vaccine, and myopericarditis after smallpox vaccination,
whereas the suspected association between hepatitis B
vaccine and multiple sclerosis has not been further
confirmed, even though it has been recently reconsidered,
and the one between childhood immunization and type 1
diabetes seems by now to be definitively gone down.
Larger epidemiological studies are needed to obtain more
reliable data in most suggested associations.
Read More:
http://informahealthcare.com/doi/abs/10.3109/08830181003746304
Vaccines, in several reports
were found to be temporally followed by a new onset of
autoimmune diseases. The same mechanisms that act in
infectious invasion of the host, apply equally to the
host response to vaccination. It has been accepted for
diphtheria and tetanus toxoid, polio and measles
vaccines and GBS. Also this theory has been accepted for
MMR vaccination and development of autoimmune
thrombocytopenia, MS has been associated with HBV
vaccination.
Read More:
http://informahealthcare.com/doi/abs/10.1080/08916930500050277
Hepatitis B infection is one
of the most important causes of acute and chronic liver
disease. During the 1980s, genetically engineered
hepatitis B vaccines (HBVs) were introduced in the
United States. A large-series of serious autoimmune
conditions have been reported following HBVs, despite
the fact that HBVs have been reported to be “generally
well-tolerated.” A case-control epidemiological study
was conducted to evaluate serious autoimmune adverse
events prospectively reported to the vaccine adverse
events reporting system (VAERS) database following HBVs,
in comparison to an age, sex, and vaccine year matched
unexposed tetanus-containing vaccine (TCV) group for
conditions that have been previously identified on an a
priori basis from case-reports. Adults receiving HBV had
significantly increased odds ratios (OR) for multiple
sclerosis (OR = 5.2, p < 0.0003, 95% Confidence Interval
(CI) = 1.9 – 20), optic neuritis (OR = 14, p < 0.0002,
95% CI = 2.3 – 560), vasculitis (OR = 2.6, p < 0.04, 95%
CI = 1.03 – 8.7), arthritis (OR = 2.01, p < 0.0003, 95%
CI = 1.3 – 3.1), alopecia (OR = 7.2, p < 0.0001, 95% CI
= 3.2 – 20), lupus erythematosus (OR = 9.1, p < 0.0001,
95% CI = 2.3 – 76), rheumatoid arthritis (OR = 18, p <
0.0001, 95% CI = 3.1 – 740), and thrombocytopenia (OR =
2.3, p < 0.04, 95% CI = 1.02 – 6.2) in comparison to the
TCV group. Minimal confounding or systematic error was
observed. Despite the negative findings of the present
study regarding the rare serious adverse effects of HBVs,
it is clear that HBV does, indeed, offer significant
benefits, but it is also clear that chances of exposure
to hepatitis B virus in adults is largely life-style
dependent. Adults should make an informed consent
decision, weighing the risks and benefits of HBV, as to
whether or not to be immunized
http://www.ncbi.nlm.nih.gov/pubmed/16206512
HBV was associated with a
number of serious conditions and positive re-challenge
or significant exacerbation of symptoms following
immunization. There were 415 arthritis, 166 rheumatoid
arthritis, 130 myelitis, 4 SLE, 100 optic neuritis, 101
GBS, 29 glomerulonephritis, 283 pancytopenia/thrombocytopenia,
and 183 MS events reportedfollowing HBV A total of 465
positive re-challenge adverse events were observed
following adult HBV that occurred sooner and with more
severity than initial adverse event reports. A
case-report of arthritis occurring in identical twins
was also identified. [personal note: between 1 and 10
percent of adverse events are actually reported
according to the FDAs David Kessler)
http://www.ncbi.nlm.nih.gov/pubmed/15638050
Viral proteins having
molecular mimicry with self-proteins in the CNS can
prime genetically susceptible individuals. Once this
priming has occurred, an immunologic challenge could
result in disease through bystander activation by
cytokines.
Read More:
http://informahealthcare.com/doi/abs/10.1080/08916930500484799
Nevertheless, allergy and,
to a lesser extent, autoimmunity have repeatedly been
described or suspected as rare adverse consequences of
human vaccines. The mechanisms of these adverse
reactions are ill-elucidated, if at all. No animal
models have been adequately standardized and validated
to predict the risk of allergy and autoimmunity
associated with vaccines. However, a number of existing
models can be considered for use, but need refinement to
be applied to vaccine evaluation. Finally, because the
preclinical safety evaluation has not received much
attention in the past, efforts should be paid to design
specific and cost-effective procedures to meet the
current expectations.
http://www.sciencedirect.com/science/article/pii/S0300483X02000562
After reviewing the 27 cases
of vasculitis after hepatitis B vaccination reported in
the current literature, the authors suggest that, in
some cases, vaccination may be the triggering factor for
vasculitis in individuals with a genetic predisposition.
Physicians should be aware of this possible association.
http://www.sciencedirect.com/science/article/pii/S0953620508000770
Mumps resurgences in the
United States: A historical perspective on unexpected
elements.
The 2006 epidemic followed
this pattern, with two unique variations: it was
preceded by a period of very high vaccination rates and
very low disease incidence and was characterized by
two-dose failure rates among adults vaccinated in
childhood. Data from the past 80 years suggest that
preventing future mumps epidemics will depend on
innovative measures to detect and eliminate build-up of
susceptibles among highly vaccinated populations
http://www.ncbi.nlm.nih.gov/pubmed/19815120
Subacute thyroiditis and
dyserythropoesis after influenza vaccination suggesting
immune dysregulation.
http://www.ncbi.nlm.nih.gov/pubmed/22111471
However, a 2006 epidemic
involved >5700 cases nationwide, with many reported
among fully vaccinated college students.. A large mumps
outbreak occurred despite high two-dose vaccination
coverage in a population most of whom had received the
second dose >10 years before. Two-dose vaccine
effectiveness was similar to previous one-dose estimates.
Further studies are needed to examine the persistence of
two-dose mumps vaccine-induced immunity and to determine
whether US mumps elimination can be achieved with the
current vaccination strategy.
http://www.ncbi.nlm.nih.gov/pubmed/18539365
The first outbreak involved
13 high-school students (median age 14 yr): 9 who had
previously received 2 doses of measles-mumps-rubella
vaccine (MMR) and 4 who received a single dose. The
second outbreak comprised 19 cases of mumps among
students and some staff at a local university (median
age 23 yr), of whom 18 had received only 1 dose of MMR
(the other received a second dose). The viruses
identified in the outbreaks were phylogenetically
similar and belonged to a genotype commonly reported in
the UK. The virus from the second outbreak is identical
to the strain currently circulating in the UK and United
States.
INTERPRETATION:
The predominance in these outbreaks of infected people
of university age not only highlights an environment
with potential for increased transmission but also
raises questions about the efficacy of the MMR vaccine.
The people affected may represent a “lost cohort” who do
not have immunity from natural mumps infection and were
not offered a 2-dose schedule. Given the current level
of mumps activity around the world, clinicians should
remain vigilant for symptoms of mumps.
http://www.ncbi.nlm.nih.gov/pubmed/16940266
Persistence of maternal
antibody in infants beyond 12 months: Mechanism of
measles vaccine failure
A serologic study was made in 34 children immunized
against measles at the age of 12 months. Using a
sensitive virus neutralization test, it was found that
many of the children had pre-existing maternal antibody
to measles virus. (this was written in 1977 back when
mothers were actually passing immunity to their children..this
is just an example of natural immunity being passed from
mother to child..something that vaccination cannot and
will not ever do.)
http://www.sciencedirect.com/science/article/pii/S0022347677810214
The study, which analyzed
data from 2009-2011, found that white, college-educated
mothers over the age of 35 were most likely to report
that they had delayed or skipped immunizations for their
children. There’s no consensus as to why that is the
case, Young said. [hmmm..lets try to help them come to a
clear consensus.. could intellence level be a factor?
could age play a role because mothers over 35 have had
more time to witness what vaccination can do?]
Read more here:
http://www.adn.com/2013/04/22/2875131/more-alaskans-hesitant-about-vaccines.html#storylink=cpy
“A Positive Association
found between Autism Prevalence and Childhood
Vaccination uptake across the U.S. Population”
The reason for the rapid
rise of autism in the United States that began in the
1990s is a mystery. Although individuals probably have a
genetic predisposition to develop autism, researchers
suspect that one or more environmental triggers are also
needed. One of those triggers might be the battery of
vaccinations that young children receive. Using
regression analysis and controlling for family income
and ethnicity, the relationship between the proportion
of children who received the recommended vaccines by age
2 years and the prevalence of autism (AUT) or speech or
language impairment (SLI) in each U.S. state from 2001
and 2007 was determined. A positive and statistically
significant relationship was found: The higher the
proportion of children receiving recommended
vaccinations, the higher was the prevalence of AUT or
SLI. A 1% increase in vaccination was associated with an
additional 680 children having AUT or SLI. Neither
parental behavior nor access to care affected the
results, since vaccination proportions were not
significantly related (statistically) to any other
disability or to the number of pediatricians in a U.S.
state. The results suggest that although mercury has
been removed from many vaccines, other culprits may link
vaccines to autism. Further study into the relationship
between vaccines and autism is warranted
full text:
http://www.theoneclickgroup.co.uk/documents/vaccines/Vaccine%20and%20Autism%20correlation%20US%202011%20J%20Tox%20Env%20Health.pdf
“CDC officials discuss
neurological damage from vaccines in secret meeting –
Simpsonwood” You can read this clearly for yourself if
you access the pdf transcript that was obtained via FOIA
http://therefusers.com/refusers-newsroom/cdc-officials-discuss-neurological-damage-from-vaccines-in-secret-meeting-simpsonwood/#.UYM4l07D_IV
“The odds of having a
history of asthma was twice as great among vaccinated
subjects than among unvaccinated subjects The odds of
having had any allergy-related respiratory symptom in
the past 12 months was 63% greater among vaccinated
subjects than unvaccinated subjects”
http://www.ncbi.nlm.nih.gov/pubmed/10714532
Nanomaterials can be
transported by monocyte-lineage cells to DLNs, blood and
spleen, and, similarly to HIV, may use CCL2-dependent
mechanisms to penetrate the brain. This occurs at a very
low rate in normal conditions explaining good overall
tolerance of alum despite its strong neurotoxic
potential. However, continuously escalating doses of
this poorly biodegradable adjuvant in the population may
become insidiously unsafe, especially in the case of
overimmunization or immature/altered blood brain barrier
or high constitutive CCL-2 production.
http://www.biomedcentral.com/1741-7015/11/99
Autism is a condition
characterized by impaired cognitive and social skills,
associated with compromised immune function. The
incidence is alarmingly on the rise, and environmental
factors are increasingly suspected to play a role. This
paper investigates word frequency patterns in the U.S.
CDC Vaccine Adverse Events Reporting System (VAERS)
database. Our results provide strong evidence supporting
a link between autism and the aluminum in vaccines. A
literature review showing toxicity of aluminum in human
physiology offers further support. Mentions of autism in
VAERS increased steadily at the end of the last century,
during a period when mercury was being phased out, while
aluminum adjuvant burden was being increased. Using
standard log-likelihood ratio techniques, we identify
several signs and symptoms that are significantly more
prevalent in vaccine reports after 2000, including
cellulitis, seizure, depression, fatigue, pain and death,
which are also significantly associated with
aluminum-containing vaccines. We propose that children
with the autism diagnosis are especially vulnerable to
toxic metals such as aluminum and mercury due to
insufficient serum sulfate and glutathione. A strong
correlation between autism and the MMR (Measles, Mumps,
Rubella) vaccine is also observed, which may be
partially explained via an increased sensitivity to
acetaminophen administered to control fever.
Tratto da:
http://treasoncast.com/2014/04/05/anti-vaccination-peer-reviewd-research-list/
Continua da e in:
Autismo Refenze - 1
+
Autismo Refenze
2 +
Amish senza autismo
perche' NON vaccinano
e QUI:
http://healthimpactnews.com/2014/the-vaccine-autism-cover-up-how-one-doctors-career-was-destroyed-for-telling-the-truth/
E questa è solo una piccolissima parte della Bibliografia esistente sui
danni
da vaccino !
VACCINS DAMAGES +
Bibliografia
+ Bibliografia
2
+
Bibliografia 3
+
Bibliografia 4 +
Sostanze
eterologhe nei vaccini e reazioni
+
INGREDIENTI TOSSICI anche OCCULTI,
di alcuni VACCINI analizzati +
Contenuto nel vaccini Trivalenti
(difpertal) +
Come si producono i Vaccinii
vedi:
Bibliografia
Danni dei vaccini +
Bibliografia danni
2 +
1.000 studi sui Danni dei Vaccini
